fluorouracil has been researched along with Alopecia Cicatrisata in 118 studies
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In DaVINCI, a randomised phase II trial, patients with advanced colorectal cancer were randomly allocated to: Combination therapy (FOLFIRI), irinotecan (180 mg/m(2) IV over 90 min, day 1), 5-fluorouracil (400mg/m(2) IV bolus and 2400 mg/m(2) by 46-hour infusion from day 1) and folinic acid (20mg/m(2) IV bolus, day 1), 2-weekly; or Single-agent, irinotecan (350 mg/m(2) IV over 90 min), 3-weekly." | 10.25 | Single-agent irinotecan or FOLFIRI as second-line chemotherapy for advanced colorectal cancer; results of a randomised phase II study (DaVINCI) and meta-analysis [corrected]. ( Boland, A; Brown, C; Buck, M; Clarke, SJ; Gebski, V; Goldstein, D; Jeffrey, GM; Lowenthal, RM; Ransom, DT; Simes, RJ; Tebbutt, NC; van Hazel, GA; Yip, S; Zalcberg, J, 2011) |
| "The present study aimed to evaluate efficacy and adverse effects of Nimotuzumab combined with docetaxel-cisplatin-fluorouracil regimen in the treatment of advanced oral carcinoma." | 9.19 | Efficacy of nimotuzumab combined with docetaxel-cisplatin-fluorouracil regimen in treatment of advanced oral carcinoma. ( Gu, QP; Guo, W; Li, ZP; Meng, J; Meng, QF; Si, YM; Zhang, J; Zhuang, QW, 2014) |
| "Postmenopausal patients with breast cancer and positive nodes, deep invasion or size exceeding 5 cm were randomly assigned to 1 year of tamoxifen, or cyclophosphamide 600 mg/m2, methotrexate 40 mg/m2 and fluorouracil 600 mg/m2 intravenously on day 1 every 4 weeks for nine cycles plus tamoxifen (CMFT)." | 9.17 | One year of adjuvant tamoxifen compared with chemotherapy and tamoxifen in postmenopausal patients with stage II breast cancer. ( Andersen, J; Andersson, M; Cold, S; Ejlertsen, B; Elversang, J; Jensen, MB; Mouridsen, HT; Nielsen, DL; Rasmussen, BB, 2013) |
| "Trastuzumab in combination with capecitabine is highly active in women with HER2-overexpressing metastatic breast cancer and is well tolerated." | 9.13 | A phase II study of trastuzumab and capecitabine for patients with HER2-overexpressing metastatic breast cancer: Japan Breast Cancer Research Network (JBCRN) 00 Trial. ( Iwase, S; Kitamura, K; Nagumo, Y; Odagiri, H; Yamamoto, C; Yamamoto, D, 2008) |
| " once every 3 weeks was assessed in 60 patients with advanced colorectal cancer (CRC) showing failure to 5-fluorouracil (5-FU) treatment." | 9.10 | Irinotecan (CPT-11) in metastatic colorectal cancer patients resistant to 5-fluorouracil (5-FU): a phase II study. ( Abad, A; Antón, A; Aranda, E; Balcells, M; Carrato, A; Cervantes, A; Díaz-Rubio, E; Fenández-Martos, C; Gallén, M; Huarte, L; Marcuello, E; Massutti, B; Sastre, J, 2003) |
| "To compare the response rate, efficacy parameters, and toxicity profile of oral capecitabine with bolus intravenous (IV) fluorouracil plus leucovorin (5-FU/LV) as first-line treatment in patients with metastatic colorectal cancer." | 9.09 | Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. ( Ansari, R; Batist, G; Burger, HU; Cox, J; Harrison, E; Hoff, PM; Kocha, W; Kuperminc, M; Maroun, J; Osterwalder, B; Walde, D; Weaver, C; Wong, AO; Wong, R, 2001) |
| "This study evaluated the toxicity and efficacy of topical topitriol (calcitriol, 1,25-dihydroxyvitamin D3) to prevent chemotherapy-induced alopecia (CIA)." | 9.09 | A phase I trial of topical topitriol (calcitriol, 1,25-dihydroxyvitamin D3) to prevent chemotherapy-induced alopecia. ( Griffin, T; Hidalgo, M; Medina, G; Rinaldi, D; Turner, J; Von Hoff, DD, 1999) |
| " Topical minoxidil has been shown to be effective for androgenetic alopecia and alopecia areata." | 9.08 | A randomized trial of minoxidil in chemotherapy-induced alopecia. ( Bandstra, BA; Compton, LD; Duvic, M; Farmer, KL; Hortobagyi, GN; Hymes, SR; Lemak, NA; Trancik, RJ; Valero, V, 1996) |
| "To determine whether a combination chemotherapy regimen that contains epirubicin (fluorouracil, epirubicin, and cyclophosphamide [FEC]) is superior to the standard cyclophosphamide, methotrexate, and fluorouracil (CMF) combination in premenopausal women with axillary node-positive operable breast cancer." | 9.08 | Adjuvant cyclophosphamide, methotrexate, and fluorouracil versus fluorouracil, epirubicin, and cyclophosphamide chemotherapy in premenopausal women with axillary node-positive operable breast cancer: results of a randomized trial. The International Collab ( Aapro, M; Amadori, D; Bliss, JM; Chilvers, CE; Coombes, G; Coombes, RC; Espié, M; Ferreira, EP; Gambrosier, P; Marty, M; McArdle, C; Morvan, F; Pérez-López, FR; Richards, M; Vassilopoulos, P; Villar-Grimalt, A; Wils, J; Woods, EM, 1996) |
| "The aim of this study was to investigate the effects of adding interferon alfa-2b (IFN) to protracted venous infusion fluorouracil (PVI 5-FU) from the start of treatment in patients with advanced colorectal cancer." | 9.08 | Impact of protracted venous infusion fluorouracil with or without interferon alfa-2b on tumor response, survival, and quality of life in advanced colorectal cancer. ( Ahmed, F; Cunningham, D; Findlay, M; Hickish, T; Hill, M; Middleton, G; Nicolson, V; Norman, A; Watson, M; Webb, A, 1995) |
| "The French Epirubicin Study Group carried out a randomized trial comparing epirubicin alone 75 mg/m2 with fluorouracil (5FU) 500 mg/m2, cyclophosphamide 500 mg/m2, and epirubicin 50 mg/m2 (FEC 50) and 5FU 500 mg/m2, cyclophosphamide 500 mg/m2, and epirubicin 75 mg/m2 (FEC 75) as first treatment for advanced breast cancer patients." | 9.07 | A prospective randomized trial comparing epirubicin monochemotherapy to two fluorouracil, cyclophosphamide, and epirubicin regimens differing in epirubicin dose in advanced breast cancer patients. The French Epirubicin Study Group. ( , 1991) |
| "As of August 1984, 115 women with advanced breast cancer have been randomized to receive a combination of either cyclophosphamide, Novantrone (mitoxantrone) and 5-fluorouracil (CNF) or cyclophosphamide, Adriamycin (doxorubicin) and 5-fluorouracil (CAF)." | 9.05 | A randomized multicenter trial of cyclophosphamide, Novantrone and 5-fluorouracil (CNF) versus cyclophosphamide, Adriamycin and 5-fluorouracil (CAF) in patients with metastatic breast cancer. ( Bennett, JM; Byrne, P; DeConti, R; Desai, A; Doroshow, J; Krementz, E; Muggia, F; Plotkin, D; Vogel, C; White, C, 1985) |
| "Raltitrexed-based chemotherapy regimen leads to an equivalent overall survival and response rates with acceptable toxicities compared to traditional 5-fluorouracil-based regimen in patients with advanced colorectal cancer." | 8.90 | Raltitrexed-based chemotherapy for advanced colorectal cancer. ( Hong, W; Huang, Q; Liu, Y; Sun, X; Wu, J; Wu, W, 2014) |
| "To review available data and implications for nurses of combination regimens containing capecitabine for metastatic breast cancer." | 8.85 | Capecitabine-based combination therapy for breast cancer: implications for nurses. ( Frye, DK, 2009) |
| "We analyzed 68 female Japanese patients with breast cancer (median age 53 years, range 29-76 years) who received perioperative adjuvant chemotherapy with fluorouracil/epirubicin/cyclophosphamide (FEC) and taxane." | 8.02 | Prospective observational study of chemotherapy-induced alopecia after sequential FEC + taxane and the effects of age in breast cancer patients. ( Fujii, T; Honda, C; Ichiba, K; Kurozumi, S; Nakazawa, Y; Obayashi, S; Ogino, M; Shirabe, K; Tokuda, S; Yajima, R, 2021) |
| "To analyze the clinical and histological features of permanent alopecia following a sequential fluorouracil/epirubicin/cyclophosphamide (FEC) and docetaxel regimen for adjuvant breast cancer treatment." | 7.78 | Permanent scalp alopecia related to breast cancer chemotherapy by sequential fluorouracil/epirubicin/cyclophosphamide (FEC) and docetaxel: a prospective study of 20 patients. ( Bessis, D; Dereure, O; Frouin, E; Guillot, B; Jacot, W; Kluger, N; Poujol, S; Rigau, V; Romieu, G, 2012) |
| "We evaluated the safety and efficacy of primary systemic chemotherapy (PSC) with docetaxel (DOC), epirubicin (EPI) and capecitabine (Xeloda:XLD) in 10 patients with advanced breast cancer." | 7.73 | [Pilot study of primary systemic chemotherapy with docetaxel (DOC), epirubicin (EPI) and capecitabine (Xeloda) in patients with advanced breast cancer]. ( Hamada, K; Kubota, K; Mori, S; Nakagawa, A; Suzuki, N; Tagaya, N, 2006) |
| "The purpose of this study was to investigate the side-effects experienced by patients with colorectal cancer receiving 5-fluorouracil + folinic acid chemotherapy." | 7.70 | Patients' experiences of chemotherapy: side-effects associated with 5-fluorouracil + folinic acid in the treatment of colorectal cancer. ( Dikken, C; Sitzia, J, 1998) |
| "Escalating doses of cyclophosphamide were given every 3 weeks as adjuvant treatment for women operated for breast cancer to determine the maximum tolerated dose of cyclophosphamide that can be given with constant doses of methotrexate (40 mg/m2) and 5-FU (600 mg/m2; CMF) as an outpatient treatment without the routine use of granulocyte colony-stimulating growth factor (G-CSF)." | 7.70 | Intensified adjuvant cyclophosphamide, methotrexate and 5-fluorouracil therapy: a dose-finding study for ambulatory patients with breast cancer. ( Hietanen, P; Joensuu, H; Teerenhovi, L, 1999) |
| "Eighteen patients (17 evaluable for response) with metastatic breast cancer were treated with mitoxantrone 10 mg/m2 day 1, followed by 5-fluorouracil 375 mg/m2 day 1-5, and high-dose leucovorin 500 mg/m2 day 1-5 given every 28 days." | 7.69 | Mitoxantrone, 5-FU, and leucovorin in breast cancer. ( Honig, SF; Swain, SM, 1994) |
| "Twenty-nine patients with metastatic breast cancer were treated with fluorouracil, adriamycin, cyclophosphamide (FAC), and methotrexate (MTX), with or without leukovorin rescue." | 7.67 | Combination chemotherapy for metastatic breast cancer with fluorouracil, adriamycin, cyclophosphamide, and methotrexate. ( Aboud, A; Blumenschein, GR; Buzdar, AU; Hortobagyi, GN; Yap, HY, 1984) |
| "In our wide experience of treating advanced breast carcinoma with chemotherapy, the combination of doxorubicin (DOX), vincristine (VCR), cyclophosphamide (CPM) and fluorouracil (FU) gave a complete plus partial response rate of over 60%, with 100% alopecia and frequent cardiac toxicity depending on total dose." | 7.67 | Mitoxantrone combined to vincristine, cyclophosphamide and fluorouracil in advanced breast cancer. ( Armand, JP; Cappelaere, P; Delgado, M; Grimbert, J; Keiling, R; Mathe, G; Metz, R; Misset, JL; Prevot, G, 1985) |
| "Thirty patients with advanced breast cancer, not pretreated with chemotherapy, received a polychemotherapy regimen containing mitoxantrone, fluorouracil and cyclophosphamide at the dose of 10 mg/m2, 500 mg/m2 and 500 mg/m2 i." | 7.67 | Mitoxantrone, 5-fluorouracil and cyclophosphamide in advanced breast cancer. ( Canova, N; Ercolino, L; Martoni, A; Pannuti, F; Rani, P, 1988) |
| "Combination three-drug chemotherapy with adriamycin (ADM), cyclophosphamide (CPM), and 5-fluorouracil (5-FU) was performed in 24 cases of advanced bladder cancer who underwent surgical treatment, and three cases with recurrent or metastatic bladder cancer." | 7.66 | Combination chemotherapy for advanced bladder cancer with adriamycin, cyclophosphamide, and 5-fluorouracil. ( Machida, T; Masuda, F; Ohishi, Y; Tashiro, K, 1983) |
| "After perioperative adjuvant chemotherapy of a sigma-adenocarcinoma with 400 mg peptichemio and 500 mg 5-fluorouracil a 61-year-old woman developed a severe intoxication: myelosuppression with pancytopenia, gastroenteritis and ulcerative proctitis, toxic hepato- and myocardiopathy, impaired renal function and alopecia." | 7.66 | [Severe intoxication after combined chemotherapy of a sigma-adenocarcinoma with peptichemio and 5-fluorouracil (author's transl)]. ( Gasser, RW; Schmalzl, F, 1982) |
| "Patients (n = 567) with metastatic colorectal cancer were randomly assigned to receive FLIRI or Lv5FU2-IRI." | 6.73 | A randomized phase III multicenter trial comparing irinotecan in combination with the Nordic bolus 5-FU and folinic acid schedule or the bolus/infused de Gramont schedule (Lv5FU2) in patients with metastatic colorectal cancer. ( Albertsson, M; Balteskard, L; Berglund, A; Byström, P; Garmo, H; Glimelius, B; Heikkilä, R; Keldsen, N; Pfeiffer, P; Starkhammar, H; Sørbye, H; Tveit, K, 2008) |
| "Randomized controlled trials (RCTs) investigating the efficacy and safety of IRI chemotherapy combined with fluoropyrimidine compared with IRI alone for the treatment of patients with advanced CRC, regardless of treatment line settings." | 6.53 | Irinotecan chemotherapy combined with fluoropyrimidines versus irinotecan alone for overall survival and progression-free survival in patients with advanced and/or metastatic colorectal cancer. ( Repana, D; Van Hemelrijck, M; Wardhana, A; Watkins, J; Wulaningsih, W; Yoshuantari, N, 2016) |
| "In DaVINCI, a randomised phase II trial, patients with advanced colorectal cancer were randomly allocated to: Combination therapy (FOLFIRI), irinotecan (180 mg/m(2) IV over 90 min, day 1), 5-fluorouracil (400mg/m(2) IV bolus and 2400 mg/m(2) by 46-hour infusion from day 1) and folinic acid (20mg/m(2) IV bolus, day 1), 2-weekly; or Single-agent, irinotecan (350 mg/m(2) IV over 90 min), 3-weekly." | 6.25 | Single-agent irinotecan or FOLFIRI as second-line chemotherapy for advanced colorectal cancer; results of a randomised phase II study (DaVINCI) and meta-analysis [corrected]. ( Boland, A; Brown, C; Buck, M; Clarke, SJ; Gebski, V; Goldstein, D; Jeffrey, GM; Lowenthal, RM; Ransom, DT; Simes, RJ; Tebbutt, NC; van Hazel, GA; Yip, S; Zalcberg, J, 2011) |
| " In April 2004, she had a recurrence manifesting itself as bone metastasis, partly because of poor compliance with the hospital-visit and dosing schedules." | 5.34 | [A patient with advanced recurrent breast cancer who firmly resisted hair loss and was then treated by combination therapy with high-dose toremifene and capecitabine]. ( Akahane, T; Chiba, T; Hashimoto, Y; Yano, H, 2007) |
| "The present study aimed to evaluate efficacy and adverse effects of Nimotuzumab combined with docetaxel-cisplatin-fluorouracil regimen in the treatment of advanced oral carcinoma." | 5.19 | Efficacy of nimotuzumab combined with docetaxel-cisplatin-fluorouracil regimen in treatment of advanced oral carcinoma. ( Gu, QP; Guo, W; Li, ZP; Meng, J; Meng, QF; Si, YM; Zhang, J; Zhuang, QW, 2014) |
| "Postmenopausal patients with breast cancer and positive nodes, deep invasion or size exceeding 5 cm were randomly assigned to 1 year of tamoxifen, or cyclophosphamide 600 mg/m2, methotrexate 40 mg/m2 and fluorouracil 600 mg/m2 intravenously on day 1 every 4 weeks for nine cycles plus tamoxifen (CMFT)." | 5.17 | One year of adjuvant tamoxifen compared with chemotherapy and tamoxifen in postmenopausal patients with stage II breast cancer. ( Andersen, J; Andersson, M; Cold, S; Ejlertsen, B; Elversang, J; Jensen, MB; Mouridsen, HT; Nielsen, DL; Rasmussen, BB, 2013) |
| "Trastuzumab in combination with capecitabine is highly active in women with HER2-overexpressing metastatic breast cancer and is well tolerated." | 5.13 | A phase II study of trastuzumab and capecitabine for patients with HER2-overexpressing metastatic breast cancer: Japan Breast Cancer Research Network (JBCRN) 00 Trial. ( Iwase, S; Kitamura, K; Nagumo, Y; Odagiri, H; Yamamoto, C; Yamamoto, D, 2008) |
| " This study determined the maximum-tolerated dose (MTD), toxicity, and pharmacokinetics of irinotecan (CPT-11), capecitabine, and epirubicin in patients with metastatic adenocarcinoma of lung, breast, or gastrointestinal tract." | 5.13 | Phase I dose escalation study with irinotecan, capecitabine, epirubicin, and granulocyte colony-stimulating factor support for patients with solid malignancies. ( Becerra, CR; Frenkel, EP; Tavana, D; Tran, HT; Verma, UN; Williams, NS, 2008) |
| "Breast cancer patients who were about to receive cycles of chemotherapy with cyclophosphamide 600 mg m(-2), methotrexate 40 mg m(-2) and 5-fluorouracil 600 mg m(-2) were recruited and randomized to receive calcipotriol scalp solution 50 microg mL(-1) or vehicle." | 5.11 | 'Atrophic telogen effluvium' from cytotoxic drugs and a randomized controlled trial to investigate the possible protective effect of pretreatment with a topical vitamin D analogue in humans. ( Bleiker, TO; Hutchinson, PE; Nicolaou, N; Traulsen, J, 2005) |
| " once every 3 weeks was assessed in 60 patients with advanced colorectal cancer (CRC) showing failure to 5-fluorouracil (5-FU) treatment." | 5.10 | Irinotecan (CPT-11) in metastatic colorectal cancer patients resistant to 5-fluorouracil (5-FU): a phase II study. ( Abad, A; Antón, A; Aranda, E; Balcells, M; Carrato, A; Cervantes, A; Díaz-Rubio, E; Fenández-Martos, C; Gallén, M; Huarte, L; Marcuello, E; Massutti, B; Sastre, J, 2003) |
| "To compare the response rate, efficacy parameters, and toxicity profile of oral capecitabine with bolus intravenous (IV) fluorouracil plus leucovorin (5-FU/LV) as first-line treatment in patients with metastatic colorectal cancer." | 5.09 | Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. ( Ansari, R; Batist, G; Burger, HU; Cox, J; Harrison, E; Hoff, PM; Kocha, W; Kuperminc, M; Maroun, J; Osterwalder, B; Walde, D; Weaver, C; Wong, AO; Wong, R, 2001) |
| "This study evaluated the toxicity and efficacy of topical topitriol (calcitriol, 1,25-dihydroxyvitamin D3) to prevent chemotherapy-induced alopecia (CIA)." | 5.09 | A phase I trial of topical topitriol (calcitriol, 1,25-dihydroxyvitamin D3) to prevent chemotherapy-induced alopecia. ( Griffin, T; Hidalgo, M; Medina, G; Rinaldi, D; Turner, J; Von Hoff, DD, 1999) |
| " Topical minoxidil has been shown to be effective for androgenetic alopecia and alopecia areata." | 5.08 | A randomized trial of minoxidil in chemotherapy-induced alopecia. ( Bandstra, BA; Compton, LD; Duvic, M; Farmer, KL; Hortobagyi, GN; Hymes, SR; Lemak, NA; Trancik, RJ; Valero, V, 1996) |
| "The aim of this study was to investigate the effects of adding interferon alfa-2b (IFN) to protracted venous infusion fluorouracil (PVI 5-FU) from the start of treatment in patients with advanced colorectal cancer." | 5.08 | Impact of protracted venous infusion fluorouracil with or without interferon alfa-2b on tumor response, survival, and quality of life in advanced colorectal cancer. ( Ahmed, F; Cunningham, D; Findlay, M; Hickish, T; Hill, M; Middleton, G; Nicolson, V; Norman, A; Watson, M; Webb, A, 1995) |
| "To determine whether a combination chemotherapy regimen that contains epirubicin (fluorouracil, epirubicin, and cyclophosphamide [FEC]) is superior to the standard cyclophosphamide, methotrexate, and fluorouracil (CMF) combination in premenopausal women with axillary node-positive operable breast cancer." | 5.08 | Adjuvant cyclophosphamide, methotrexate, and fluorouracil versus fluorouracil, epirubicin, and cyclophosphamide chemotherapy in premenopausal women with axillary node-positive operable breast cancer: results of a randomized trial. The International Collab ( Aapro, M; Amadori, D; Bliss, JM; Chilvers, CE; Coombes, G; Coombes, RC; Espié, M; Ferreira, EP; Gambrosier, P; Marty, M; McArdle, C; Morvan, F; Pérez-López, FR; Richards, M; Vassilopoulos, P; Villar-Grimalt, A; Wils, J; Woods, EM, 1996) |
| "The French Epirubicin Study Group carried out a randomized trial comparing epirubicin alone 75 mg/m2 with fluorouracil (5FU) 500 mg/m2, cyclophosphamide 500 mg/m2, and epirubicin 50 mg/m2 (FEC 50) and 5FU 500 mg/m2, cyclophosphamide 500 mg/m2, and epirubicin 75 mg/m2 (FEC 75) as first treatment for advanced breast cancer patients." | 5.07 | A prospective randomized trial comparing epirubicin monochemotherapy to two fluorouracil, cyclophosphamide, and epirubicin regimens differing in epirubicin dose in advanced breast cancer patients. The French Epirubicin Study Group. ( , 1991) |
| "One hundred eighty-seven patients with histologically proven advanced pancreatic adenocarcinoma were randomly assigned to therapy with 5-fluorouracil (5-FU) alone, to the Mallinson regimen (combined and sequential 5-FU, cyclophosphamide, methotrexate, vincristine, and mitomycin C), or to combined 5-FU, doxorubicin, and cisplatin (FAP)." | 5.06 | A phase III trial on the therapy of advanced pancreatic carcinoma. Evaluations of the Mallinson regimen and combined 5-fluorouracil, doxorubicin, and cisplatin. ( Barlow, JF; Cullinan, S; Foley, JF; Kardinal, CG; Krook, JE; Moertel, CG; Norris, BD; Schutt, AJ; Tschetter, LK; Wieand, HS, 1990) |
| "As of August 1984, 115 women with advanced breast cancer have been randomized to receive a combination of either cyclophosphamide, Novantrone (mitoxantrone) and 5-fluorouracil (CNF) or cyclophosphamide, Adriamycin (doxorubicin) and 5-fluorouracil (CAF)." | 5.05 | A randomized multicenter trial of cyclophosphamide, Novantrone and 5-fluorouracil (CNF) versus cyclophosphamide, Adriamycin and 5-fluorouracil (CAF) in patients with metastatic breast cancer. ( Bennett, JM; Byrne, P; DeConti, R; Desai, A; Doroshow, J; Krementz, E; Muggia, F; Plotkin, D; Vogel, C; White, C, 1985) |
| "Raltitrexed-based chemotherapy regimen leads to an equivalent overall survival and response rates with acceptable toxicities compared to traditional 5-fluorouracil-based regimen in patients with advanced colorectal cancer." | 4.90 | Raltitrexed-based chemotherapy for advanced colorectal cancer. ( Hong, W; Huang, Q; Liu, Y; Sun, X; Wu, J; Wu, W, 2014) |
| "To review available data and implications for nurses of combination regimens containing capecitabine for metastatic breast cancer." | 4.85 | Capecitabine-based combination therapy for breast cancer: implications for nurses. ( Frye, DK, 2009) |
| "We analyzed 68 female Japanese patients with breast cancer (median age 53 years, range 29-76 years) who received perioperative adjuvant chemotherapy with fluorouracil/epirubicin/cyclophosphamide (FEC) and taxane." | 4.02 | Prospective observational study of chemotherapy-induced alopecia after sequential FEC + taxane and the effects of age in breast cancer patients. ( Fujii, T; Honda, C; Ichiba, K; Kurozumi, S; Nakazawa, Y; Obayashi, S; Ogino, M; Shirabe, K; Tokuda, S; Yajima, R, 2021) |
| "To evaluate the impact of sex on toxicity and efficacy outcomes among patients with metastatic colorectal cancer receiving first-line 5-fluorouracil-based regimens." | 3.91 | Impact of Sex on Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer: Pooled Analysis of 5 Randomized Trials. ( Abdel-Rahman, O, 2019) |
| "To analyze the clinical and histological features of permanent alopecia following a sequential fluorouracil/epirubicin/cyclophosphamide (FEC) and docetaxel regimen for adjuvant breast cancer treatment." | 3.78 | Permanent scalp alopecia related to breast cancer chemotherapy by sequential fluorouracil/epirubicin/cyclophosphamide (FEC) and docetaxel: a prospective study of 20 patients. ( Bessis, D; Dereure, O; Frouin, E; Guillot, B; Jacot, W; Kluger, N; Poujol, S; Rigau, V; Romieu, G, 2012) |
| "With current adjuvant chemotherapy for breast cancer, in which a combination of cyclophosphamide and an anthracycline is often used, there is no place for scalp hypothermia." | 3.77 | Scalp cooling has no place in the prevention of alopecia in adjuvant chemotherapy for breast cancer. ( Liefers, GJ; Repelaer van Driel, OJ; Tollenaar, RA; van de Velde, CJ, 1994) |
| "We evaluated the safety and efficacy of primary systemic chemotherapy (PSC) with docetaxel (DOC), epirubicin (EPI) and capecitabine (Xeloda:XLD) in 10 patients with advanced breast cancer." | 3.73 | [Pilot study of primary systemic chemotherapy with docetaxel (DOC), epirubicin (EPI) and capecitabine (Xeloda) in patients with advanced breast cancer]. ( Hamada, K; Kubota, K; Mori, S; Nakagawa, A; Suzuki, N; Tagaya, N, 2006) |
| "Escalating doses of cyclophosphamide were given every 3 weeks as adjuvant treatment for women operated for breast cancer to determine the maximum tolerated dose of cyclophosphamide that can be given with constant doses of methotrexate (40 mg/m2) and 5-FU (600 mg/m2; CMF) as an outpatient treatment without the routine use of granulocyte colony-stimulating growth factor (G-CSF)." | 3.70 | Intensified adjuvant cyclophosphamide, methotrexate and 5-fluorouracil therapy: a dose-finding study for ambulatory patients with breast cancer. ( Hietanen, P; Joensuu, H; Teerenhovi, L, 1999) |
| "The purpose of this study was to investigate the side-effects experienced by patients with colorectal cancer receiving 5-fluorouracil + folinic acid chemotherapy." | 3.70 | Patients' experiences of chemotherapy: side-effects associated with 5-fluorouracil + folinic acid in the treatment of colorectal cancer. ( Dikken, C; Sitzia, J, 1998) |
| "Eighteen patients (17 evaluable for response) with metastatic breast cancer were treated with mitoxantrone 10 mg/m2 day 1, followed by 5-fluorouracil 375 mg/m2 day 1-5, and high-dose leucovorin 500 mg/m2 day 1-5 given every 28 days." | 3.69 | Mitoxantrone, 5-FU, and leucovorin in breast cancer. ( Honig, SF; Swain, SM, 1994) |
| "Seventy-five female patients suffering from advanced breast cancer were treated with toilet mastectomy, radiotherapy and oophorectomy (if premenopausal) or tamoxifen therapy (if postmenopausal) as well as chemotherapy with cyclophosphamide, methotrexate, 5-fluorouracil and prednisone." | 3.68 | Toxicity and side-effects of combination chemohormonal therapy of advanced breast cancer. ( Dandapat, MC; Mohapatro, SK; Padhi, NC, 1992) |
| "Twenty-nine patients with metastatic breast cancer were treated with fluorouracil, adriamycin, cyclophosphamide (FAC), and methotrexate (MTX), with or without leukovorin rescue." | 3.67 | Combination chemotherapy for metastatic breast cancer with fluorouracil, adriamycin, cyclophosphamide, and methotrexate. ( Aboud, A; Blumenschein, GR; Buzdar, AU; Hortobagyi, GN; Yap, HY, 1984) |
| "Thirty patients with advanced breast cancer, not pretreated with chemotherapy, received a polychemotherapy regimen containing mitoxantrone, fluorouracil and cyclophosphamide at the dose of 10 mg/m2, 500 mg/m2 and 500 mg/m2 i." | 3.67 | Mitoxantrone, 5-fluorouracil and cyclophosphamide in advanced breast cancer. ( Canova, N; Ercolino, L; Martoni, A; Pannuti, F; Rani, P, 1988) |
| "In our wide experience of treating advanced breast carcinoma with chemotherapy, the combination of doxorubicin (DOX), vincristine (VCR), cyclophosphamide (CPM) and fluorouracil (FU) gave a complete plus partial response rate of over 60%, with 100% alopecia and frequent cardiac toxicity depending on total dose." | 3.67 | Mitoxantrone combined to vincristine, cyclophosphamide and fluorouracil in advanced breast cancer. ( Armand, JP; Cappelaere, P; Delgado, M; Grimbert, J; Keiling, R; Mathe, G; Metz, R; Misset, JL; Prevot, G, 1985) |
| " Vitamin A acid and benzoyl peroxide have brought significant advances in the topical treatment of acne." | 3.66 | [Advances in topical therapy of skin diseases (author's transl)]. ( Happle, R, 1979) |
| "A group of 47 patients with advanced breast cancer were treated with a combination of prednimustine, methotrexate, 5-FU, and tamoxifen." | 3.66 | Prednimustine in combination with methotrexate and 5-FU (PMF): a pilot study. ( Boesen, E; Mouridsen, HT, 1982) |
| "After perioperative adjuvant chemotherapy of a sigma-adenocarcinoma with 400 mg peptichemio and 500 mg 5-fluorouracil a 61-year-old woman developed a severe intoxication: myelosuppression with pancytopenia, gastroenteritis and ulcerative proctitis, toxic hepato- and myocardiopathy, impaired renal function and alopecia." | 3.66 | [Severe intoxication after combined chemotherapy of a sigma-adenocarcinoma with peptichemio and 5-fluorouracil (author's transl)]. ( Gasser, RW; Schmalzl, F, 1982) |
| "Combination three-drug chemotherapy with adriamycin (ADM), cyclophosphamide (CPM), and 5-fluorouracil (5-FU) was performed in 24 cases of advanced bladder cancer who underwent surgical treatment, and three cases with recurrent or metastatic bladder cancer." | 3.66 | Combination chemotherapy for advanced bladder cancer with adriamycin, cyclophosphamide, and 5-fluorouracil. ( Machida, T; Masuda, F; Ohishi, Y; Tashiro, K, 1983) |
| "Thirty patients with an advanced bronchogenic carcinoma were treated with a combination of adriamycin and 5-fluorouracil; in eight the size of the tumour or its metastases was reduced by over 50%, and eight further patients experienced useful relief of symptoms." | 3.65 | Treatment of advanced bronchogenic carcinoma with adriamycin and 5-fluorouracil. ( Anderson, G; Bugaighis, A; Rees, GJ, 1975) |
| "Twenty-five patients with advanced metastatic breast cancer were treated with the combination of methotrexate 60 mg/M(2) and 5-fluorouracil 700 mg/M(2) intravenously on the first and eighth days, and cyclophosphamide 100 mg/M(2) and prednisone 40 mg/M(2) by mouth daily for the first 14 days of a 28-day cycle." | 3.65 | Cyclical combination chemotherapy for advanced breast carcinoma. ( Canellos, GP; Chabner, BA; Devita, VT; Gold, GL; Schein, PS; Young, RC, 1974) |
| "Fresh patients with squamous cell carcinoma of the head and neck were enrolled in the study." | 2.73 | [Phase I/II clinical trial of induction chemotherapy with nedaplatin (CDGP), docetaxel (DOC) and 5-fluorouracil (5-FU) for squamous cell carcinoma of head and neck]. ( Iwabuchi, H; Nakayama, S; Uchiyama, K, 2007) |
| "Patients (n = 567) with metastatic colorectal cancer were randomly assigned to receive FLIRI or Lv5FU2-IRI." | 2.73 | A randomized phase III multicenter trial comparing irinotecan in combination with the Nordic bolus 5-FU and folinic acid schedule or the bolus/infused de Gramont schedule (Lv5FU2) in patients with metastatic colorectal cancer. ( Albertsson, M; Balteskard, L; Berglund, A; Byström, P; Garmo, H; Glimelius, B; Heikkilä, R; Keldsen, N; Pfeiffer, P; Starkhammar, H; Sørbye, H; Tveit, K, 2008) |
| "Patients with advanced or recurrent gastric cancer were treated with escalating doses of weekly paclitaxel as a 60 min intravenous (i." | 2.71 | Phase I evaluation of continuous 5-fluorouracil infusion followed by weekly paclitaxel in patients with advanced or recurrent gastric cancer. ( Araki, K; Hirabayashi, N; Kataoka, M; Kobayashi, M; Kojima, H; Kondo, K; Matsui, T; Miyashita, Y; Nakao, A; Nakazato, H; Sakamoto, J; Takiyama, W, 2005) |
| "Patients with advanced and recurrent gastric cancer were treated with this regimen as early phase II trial and its efficacy and toxicity were assessed." | 2.69 | Phase II study of 5-fluorouracil, pirarubicin and low-dose consecutive administration of cisplatin for advanced and recurrent gastric cancer. ( Inada, T; Kikuyama, S; Miyakita, M; Ogata, Y, 1998) |
| "Thirty-six advanced or metastatic gastric cancer and chemotherapy-naïve patients with measurable or evaluable diseases were scheduled to receive intravenous etoposide 100 mg/m2/day on days 2-4, LV 300 mg/m2/day intravenously and 5-FU 500 mg/m2/day intravenously on days 1-5, every 4 weeks." | 2.69 | Phase II study of the modified regimen of etoposide, leucovorin and 5-fluorouracil for patients with advanced gastric cancer. ( Chen, PM; Chiou, TJ; Fan, FS; Hsieh, RK; Liu, JH; Tung, SL; Wang, WS; Yen, CC, 1998) |
| " This phase I study was performed to determine the maximum tolerated dose (MTD) and side-effects of the combination, and to establish whether there is any pharmacokinetic interaction between the two compounds." | 2.69 | A phase I and pharmacokinetic study of the combination of capecitabine and docetaxel in patients with advanced solid tumours. ( Gordon, RJ; Osterwalder, B; Planting, AS; Pronk, LC; Reigner, B; Sparreboom, A; Twelves, C; Vasey, P; Verweij, J, 2000) |
| "To determine the dose-limiting toxicity of CPT-11 in combination with oxaliplatin, and the maximal tolerated dose (MTD) and the recommended dose (RD) of CPT-11 using an every two weeks schedule." | 2.69 | Dose escalation of CPT-11 in combination with oxaliplatin using an every two weeks schedule: a phase I study in advanced gastrointestinal cancer patients. ( Cvitkovic, E; Di Palma, M; Goldwasser, F; Gross-Goupil, M; Marceau-Suissa, J; Misset, JL; Tigaud, JM; Wasserman, E; Yovine, A, 2000) |
| "Leukocytopenia was more severe in group B." | 2.67 | [Sequential methotrexate/5-fluorouracil therapy with 5'-deoxy-5-fluorouridine against advanced gastric cancer: comparison between bolus injection and drip infusion of 5-fluorouracil administration. Hirosaki Cooperative Study Group for Cancer Chemotherapy] ( Ito, T; Komatsu, Y; Moriya, N; Ogasawara, H; Saito, S; Sakata, Y; Sugimoto, N; Tamura, Y; Tsushima, K; Yamada, Y, 1994) |
| "Leukopenia was more frequent in the simultaneous than in the sequential arm (p = 0." | 2.67 | A randomized phase II study comparing sequential versus simultaneous chemo-radiotherapy in patients with unresectable locally advanced squamous cell cancer of the head and neck. ( Carlini, P; Cercato, MC; Cognetti, F; Del Vecchio, MR; Giannarelli, D; Impiombato, FA; Marzetti, F; Milella, M; Pinnarò, P, 1994) |
| " No serious adverse effects were observed in any of the groups." | 2.66 | [Cooperative study of surgical adjuvant chemotherapy of colorectal cancer (first report): Investigation of background factors and adverse effects. Cooperative Study Group of Surgical Adjuvant Chemotherapy of Colorectal Cancer in Japan]. ( Abe, O; Hattori, T; Inokuchi, K; Kasai, Y; Kikuchi, K; Komi, N; Kondo, T; Kunii, Y; Ogawa, N; Taguchi, T, 1987) |
| "Squamous cell carcinoma was found in 51 patients, adenocarcinoma in 3, and anaplastic (squamous cell) carcinoma in 2 patients." | 2.65 | The value of two combined chemoradiotherapy approaches in the treatment of inoperable esophageal cancer. ( Dujmović, I; Kolarić, K; Roth, A, 1984) |
| "Leukopenia was the dose-limiting toxicity with all three regimens." | 2.64 | Combination chemotherapy and adriamycin in patients with advanced breast cancer. A Southwest Oncology Group study. ( Bonnet, JD; Braine, H; Costanzi, JJ; George, SL; Hoogstraten, B; Rivkin, SE; Samal, B; Thigpen, T, 1976) |
| "Randomized controlled trials (RCTs) investigating the efficacy and safety of IRI chemotherapy combined with fluoropyrimidine compared with IRI alone for the treatment of patients with advanced CRC, regardless of treatment line settings." | 2.53 | Irinotecan chemotherapy combined with fluoropyrimidines versus irinotecan alone for overall survival and progression-free survival in patients with advanced and/or metastatic colorectal cancer. ( Repana, D; Van Hemelrijck, M; Wardhana, A; Watkins, J; Wulaningsih, W; Yoshuantari, N, 2016) |
| " Hand-foot syndrome (HFS) is the only clinical adverse event occurring more often during capecitabine treatment." | 2.42 | Management of adverse events and other practical considerations in patients receiving capecitabine (Xeloda). ( Grothey, A; Marsé, H; Valverde, S; Van Cutsem, E, 2004) |
| "Alopecia was observed in 60% of patients." | 1.62 | Toxicity profile of taxanes in Tunisian cancer patients: A retrospective study of 90 cases. ( Ayari, J; Balti, M; Ben Abdallah, I; Ben Hassen, M; Ben Nasr, S; Doghri, Y; Fendri, S; Haddaoui, A; Trigui, E; Zribi, A, 2021) |
| " The most frequent adverse symptom of skin and subcutaneous toxicity reported in the patients treated with modified schedule of FOLFOX was pruritus (grade 1)." | 1.39 | Comparative assessment of skin and subcutaneous toxicity in patients of advanced colorectal carcinoma treated with different schedules of FOLFOX. ( Bano, N; Mateen, A; Najam, R, 2013) |
| " In April 2004, she had a recurrence manifesting itself as bone metastasis, partly because of poor compliance with the hospital-visit and dosing schedules." | 1.34 | [A patient with advanced recurrent breast cancer who firmly resisted hair loss and was then treated by combination therapy with high-dose toremifene and capecitabine]. ( Akahane, T; Chiba, T; Hashimoto, Y; Yano, H, 2007) |
| "It seems that the quality of life for breast cancer patients was affected by the extent of the alopecia." | 1.33 | [A case of advanced breast cancer markedly responding to chemo-endocrine therapy with only slight alopecia]. ( Iwakuma, N; Nagamatsu, H; Ono, H; Shirouzu, K; Terazaki, Y, 2005) |
| "50 cases of locally advanced breast cancer after complete routine and metastatic work up were subjected to trucut biopsy and the tissue evaluated immunohistochemically for apoptotic markers (bcl-2/bax ratio)." | 1.32 | Is drug-induced toxicity a good predictor of response to neo-adjuvant chemotherapy in patients with breast cancer?--a prospective clinical study. ( Bansal, A; Lyall, A; Saxena, S; Singh, JP; Singhal, V, 2004) |
| "An experience with an advanced gastric cancer patient with metastases to bilateral breasts, uterus, abdominal lymph nodes, bilateral axillary and supraclavicular lymph nodes, and bone marrow, responded extremely well to an FAP combined chemotherapy as reported here." | 1.29 | [A case of advanced gastric cancer responding to an FAP (5-FU, ADM, platinum compounds) combined chemotherapy]. ( Azuma, T; Doihara, H; Kirihara, Y; Miyahara, E; Ohashi, R; Sakamoto, N; Soga, H; Takiyama, W; Tanada, M; Yokoyama, N, 1993) |
| "Twenty-one patients were treated with sequential doses of MTX and 5-FU so as to be classified by MTX dosage into an intermediate MTX-dose group and a high MTX-dose group." | 1.27 | [Therapeutic effect of sequential doses of methotrexate (MTX) and 5-fluorouracil (5-FU) in advanced gastric cancer: comparison of intermediate-dose MTX with high-dose MTX]. ( Akazawa, S; Futatsuki, K; Honda, T; Kanda, Y; Kitagawa, H; Nakagawa, T; Nakajima, T; Suda, Y; Yoshida, S, 1985) |
| "Seventy-two women with metastatic breast cancer were treated with multiple-agent chemotherapy." | 1.26 | Combination chemotherapy in the treatment of advanced breast cancer. ( Dao, TL; Nemoto, T; Rosner, D, 1976) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 48 (40.68) | 18.7374 |
| 1990's | 24 (20.34) | 18.2507 |
| 2000's | 27 (22.88) | 29.6817 |
| 2010's | 14 (11.86) | 24.3611 |
| 2020's | 5 (4.24) | 2.80 |
| Authors | Studies |
|---|---|
| De Francia, S | 1 |
| Berchialla, P | 1 |
| Armando, T | 1 |
| Storto, S | 1 |
| Allegra, S | 1 |
| Sciannameo, V | 1 |
| Soave, G | 1 |
| Sprio, AE | 1 |
| Racca, S | 1 |
| Caiaffa, MR | 1 |
| Ciuffreda, L | 1 |
| Mussa, MV | 1 |
| Duan, BF | 1 |
| Chen, HY | 1 |
| Zheng, XM | 1 |
| He, Q | 1 |
| Heibloem, RE | 1 |
| Komen, MMC | 3 |
| Ilozumba, OUC | 1 |
| van den Hurk, CJG | 3 |
| Fujii, T | 1 |
| Ichiba, K | 1 |
| Honda, C | 1 |
| Tokuda, S | 1 |
| Nakazawa, Y | 1 |
| Ogino, M | 1 |
| Kurozumi, S | 1 |
| Obayashi, S | 1 |
| Yajima, R | 1 |
| Shirabe, K | 1 |
| Ben Nasr, S | 1 |
| Zribi, A | 1 |
| Ben Hassen, M | 1 |
| Doghri, Y | 1 |
| Ben Abdallah, I | 1 |
| Trigui, E | 1 |
| Fendri, S | 1 |
| Ayari, J | 1 |
| Balti, M | 1 |
| Haddaoui, A | 1 |
| Rossi, A | 1 |
| Fortuna, MC | 1 |
| Caro, G | 1 |
| Pigliacelli, F | 1 |
| D'Arino, A | 1 |
| Carlesimo, M | 1 |
| Nortier, JWR | 2 |
| van der Ploeg, T | 2 |
| Nieboer, P | 1 |
| van der Hoeven, JJM | 2 |
| Smorenburg, CH | 2 |
| Basset-Seguin, N | 1 |
| Abdel-Rahman, O | 1 |
| Bano, N | 1 |
| Najam, R | 1 |
| Mateen, A | 1 |
| Meng, J | 1 |
| Gu, QP | 1 |
| Meng, QF | 1 |
| Zhang, J | 1 |
| Li, ZP | 1 |
| Si, YM | 1 |
| Guo, W | 2 |
| Zhuang, QW | 1 |
| Ejlertsen, B | 1 |
| Jensen, MB | 1 |
| Elversang, J | 1 |
| Rasmussen, BB | 1 |
| Andersson, M | 2 |
| Andersen, J | 1 |
| Nielsen, DL | 1 |
| Cold, S | 1 |
| Mouridsen, HT | 3 |
| Liu, Y | 1 |
| Wu, W | 1 |
| Hong, W | 1 |
| Sun, X | 1 |
| Wu, J | 1 |
| Huang, Q | 1 |
| Wulaningsih, W | 1 |
| Wardhana, A | 1 |
| Watkins, J | 1 |
| Yoshuantari, N | 1 |
| Repana, D | 1 |
| Van Hemelrijck, M | 1 |
| Becerra, CR | 1 |
| Verma, UN | 1 |
| Tran, HT | 1 |
| Tavana, D | 1 |
| Williams, NS | 1 |
| Frenkel, EP | 1 |
| Frye, DK | 1 |
| Clarke, SJ | 1 |
| Yip, S | 1 |
| Brown, C | 1 |
| van Hazel, GA | 1 |
| Ransom, DT | 1 |
| Goldstein, D | 1 |
| Jeffrey, GM | 1 |
| Tebbutt, NC | 1 |
| Buck, M | 1 |
| Lowenthal, RM | 1 |
| Boland, A | 1 |
| Gebski, V | 1 |
| Zalcberg, J | 1 |
| Simes, RJ | 1 |
| Mohammadianpanah, M | 1 |
| Ashouri, Y | 1 |
| Hoseini, S | 1 |
| Amadloo, N | 1 |
| Talei, A | 1 |
| Tahmasebi, S | 1 |
| Nasrolahi, H | 1 |
| Mosalaei, A | 1 |
| Omidvari, S | 1 |
| Ansari, M | 1 |
| Mosleh-Shirazi, MA | 1 |
| Kluger, N | 1 |
| Jacot, W | 1 |
| Frouin, E | 1 |
| Rigau, V | 1 |
| Poujol, S | 1 |
| Dereure, O | 1 |
| Guillot, B | 1 |
| Romieu, G | 1 |
| Bessis, D | 1 |
| Zhong, LP | 1 |
| Zhang, CP | 1 |
| Ren, GX | 1 |
| William, WN | 1 |
| Sun, J | 1 |
| Zhu, HG | 1 |
| Tu, WY | 1 |
| Li, J | 2 |
| Cai, YL | 1 |
| Wang, LZ | 1 |
| Fan, XD | 1 |
| Wang, ZH | 1 |
| Hu, YJ | 1 |
| Ji, T | 1 |
| Yang, WJ | 1 |
| Ye, WM | 1 |
| He, Y | 1 |
| Wang, YA | 1 |
| Xu, LQ | 1 |
| Wang, BS | 1 |
| Kies, MS | 1 |
| Lee, JJ | 1 |
| Myers, JN | 1 |
| Zhang, ZY | 1 |
| Yamada, R | 1 |
| Yamamoto, Y | 1 |
| Morinaga, S | 1 |
| Noguchi, Y | 1 |
| Yoshida, S | 2 |
| Matsumoto, A | 1 |
| van Kuilenburg, AB | 1 |
| Baars, JW | 1 |
| Meinsma, R | 1 |
| van Gennip, AH | 1 |
| Bocci, G | 1 |
| Danesi, R | 1 |
| Allegrini, G | 1 |
| Innocenti, F | 1 |
| Di Paolo, A | 1 |
| Falcone, A | 1 |
| Conte, PF | 1 |
| Del Tacca, M | 1 |
| Louvet, C | 1 |
| Carrat, F | 1 |
| Mal, F | 1 |
| Mabro, M | 1 |
| Beerblock, K | 1 |
| Vaillant, JC | 1 |
| Cady, J | 1 |
| André, T | 1 |
| Gamelin, E | 1 |
| de Gramont, A | 1 |
| SCHELL, HW | 1 |
| MOERTEL, CG | 4 |
| REITEMEIER, RJ | 2 |
| HAHN, RG | 4 |
| HURLEY, JD | 1 |
| FALKSON, G | 2 |
| SCHULZ, EJ | 1 |
| ANSFIELD, FJ | 1 |
| Antón, A | 1 |
| Aranda, E | 1 |
| Carrato, A | 1 |
| Marcuello, E | 1 |
| Massutti, B | 1 |
| Cervantes, A | 1 |
| Abad, A | 1 |
| Sastre, J | 1 |
| Fenández-Martos, C | 1 |
| Gallén, M | 1 |
| Díaz-Rubio, E | 3 |
| Huarte, L | 1 |
| Balcells, M | 1 |
| Singhal, V | 1 |
| Singh, JP | 1 |
| Lyall, A | 1 |
| Saxena, S | 1 |
| Bansal, A | 1 |
| Marsé, H | 1 |
| Van Cutsem, E | 1 |
| Grothey, A | 1 |
| Valverde, S | 1 |
| Li, Y | 1 |
| Wu, XQ | 1 |
| Cui, HJ | 1 |
| Tan, HY | 1 |
| Terazaki, Y | 1 |
| Nagamatsu, H | 1 |
| Ono, H | 1 |
| Iwakuma, N | 1 |
| Shirouzu, K | 1 |
| Kondo, K | 1 |
| Kobayashi, M | 1 |
| Kojima, H | 1 |
| Hirabayashi, N | 1 |
| Kataoka, M | 1 |
| Araki, K | 1 |
| Matsui, T | 1 |
| Takiyama, W | 2 |
| Miyashita, Y | 1 |
| Nakazato, H | 1 |
| Nakao, A | 1 |
| Sakamoto, J | 1 |
| Bleiker, TO | 1 |
| Nicolaou, N | 1 |
| Traulsen, J | 1 |
| Hutchinson, PE | 1 |
| Suzuki, S | 1 |
| Harada, N | 1 |
| Takeo, Y | 1 |
| Tanaka, S | 1 |
| Hayashi, T | 1 |
| Suzuki, M | 1 |
| Hanyu, F | 1 |
| Prévost, A | 1 |
| Mérol, JC | 1 |
| Aimé, P | 1 |
| Moutel, K | 1 |
| Roger-Liautaud, F | 1 |
| Nasca, S | 1 |
| Legros, M | 1 |
| Coninx, P | 1 |
| Tagaya, N | 1 |
| Nakagawa, A | 1 |
| Mori, S | 1 |
| Hamada, K | 1 |
| Suzuki, N | 1 |
| Kubota, K | 1 |
| Jiang, Y | 1 |
| Qiu, XH | 1 |
| Yang, YX | 1 |
| Zhang, SQ | 1 |
| Chen, ZM | 1 |
| Uchiyama, K | 1 |
| Iwabuchi, H | 1 |
| Nakayama, S | 1 |
| Akahane, T | 1 |
| Chiba, T | 1 |
| Yano, H | 1 |
| Hashimoto, Y | 1 |
| Yamamoto, D | 1 |
| Iwase, S | 1 |
| Kitamura, K | 1 |
| Odagiri, H | 1 |
| Yamamoto, C | 1 |
| Nagumo, Y | 1 |
| Glimelius, B | 1 |
| Sørbye, H | 1 |
| Balteskard, L | 1 |
| Byström, P | 1 |
| Pfeiffer, P | 1 |
| Tveit, K | 1 |
| Heikkilä, R | 1 |
| Keldsen, N | 1 |
| Albertsson, M | 1 |
| Starkhammar, H | 1 |
| Garmo, H | 1 |
| Berglund, A | 1 |
| Puglisi, F | 1 |
| Cardellino, GG | 1 |
| Crivellari, D | 1 |
| Di Loreto, C | 1 |
| Magri, MD | 1 |
| Minisini, AM | 1 |
| Mansutti, M | 1 |
| Andreetta, C | 1 |
| Russo, S | 1 |
| Lombardi, D | 1 |
| Perin, T | 1 |
| Damante, G | 1 |
| Veronesi, A | 1 |
| Kolarić, K | 1 |
| Roth, A | 1 |
| Dujmović, I | 1 |
| Legha, SS | 2 |
| Ajani, JA | 1 |
| Blumenschein, GR | 4 |
| Hortobagyi, GN | 5 |
| Buzdar, AU | 5 |
| Pinnamaneni, K | 1 |
| Yap, HY | 3 |
| Distefano, A | 1 |
| Aboud, A | 1 |
| Tashiro, K | 1 |
| Machida, T | 1 |
| Masuda, F | 1 |
| Ohishi, Y | 1 |
| Waibel, PJ | 1 |
| Jungi, WF | 1 |
| Senn, HJ | 1 |
| Hirshaut, Y | 1 |
| Kesselheim, H | 1 |
| Vaughn, CB | 1 |
| Maniscalco-Greb, E | 1 |
| Lockhard, C | 1 |
| Groshko, G | 1 |
| Enochs, K | 1 |
| Duffin, H | 1 |
| Demitrish, M | 1 |
| Wiseman, CL | 1 |
| Gutterman, JU | 1 |
| Hersh, EM | 1 |
| Bodey, GP | 1 |
| Gasser, RW | 1 |
| Schmalzl, F | 1 |
| Sorbe, B | 1 |
| Frankendal, B | 1 |
| Boesen, E | 1 |
| Hill, M | 1 |
| Norman, A | 1 |
| Cunningham, D | 1 |
| Findlay, M | 1 |
| Watson, M | 1 |
| Nicolson, V | 1 |
| Webb, A | 1 |
| Middleton, G | 1 |
| Ahmed, F | 1 |
| Hickish, T | 1 |
| Tollenaar, RA | 1 |
| Liefers, GJ | 1 |
| Repelaer van Driel, OJ | 1 |
| van de Velde, CJ | 1 |
| Pinnarò, P | 1 |
| Cercato, MC | 1 |
| Giannarelli, D | 1 |
| Carlini, P | 1 |
| Del Vecchio, MR | 1 |
| Impiombato, FA | 1 |
| Marzetti, F | 1 |
| Milella, M | 1 |
| Cognetti, F | 1 |
| Swain, SM | 1 |
| Honig, SF | 1 |
| Yamada, Y | 1 |
| Tsushima, K | 1 |
| Sakata, Y | 1 |
| Saito, S | 1 |
| Ito, T | 1 |
| Sugimoto, N | 1 |
| Ogasawara, H | 1 |
| Tamura, Y | 1 |
| Moriya, N | 1 |
| Komatsu, Y | 1 |
| Xing, FY | 1 |
| Liu, WH | 1 |
| Dong, W | 1 |
| Zhang, SL | 1 |
| Gu, BW | 1 |
| Okazaki, K | 1 |
| Naito, H | 1 |
| Inoue, T | 1 |
| Wu, JT | 1 |
| Tamura, S | 1 |
| Miyahara, E | 1 |
| Sakamoto, N | 1 |
| Azuma, T | 1 |
| Ohashi, R | 1 |
| Kirihara, Y | 1 |
| Doihara, H | 1 |
| Yokoyama, N | 1 |
| Tanada, M | 1 |
| Soga, H | 1 |
| Singh, G | 1 |
| Singh, DP | 1 |
| Gupta, D | 1 |
| Muralikrishna, BV | 1 |
| Coombes, RC | 1 |
| Bliss, JM | 1 |
| Wils, J | 1 |
| Morvan, F | 1 |
| Espié, M | 1 |
| Amadori, D | 1 |
| Gambrosier, P | 1 |
| Richards, M | 1 |
| Aapro, M | 1 |
| Villar-Grimalt, A | 1 |
| McArdle, C | 1 |
| Pérez-López, FR | 1 |
| Vassilopoulos, P | 1 |
| Ferreira, EP | 1 |
| Chilvers, CE | 1 |
| Coombes, G | 1 |
| Woods, EM | 1 |
| Marty, M | 1 |
| Duvic, M | 1 |
| Lemak, NA | 1 |
| Valero, V | 1 |
| Hymes, SR | 1 |
| Farmer, KL | 1 |
| Trancik, RJ | 1 |
| Bandstra, BA | 1 |
| Compton, LD | 1 |
| González-Larriba, JL | 1 |
| Garcia Carbonero, I | 1 |
| Sastre Valera, J | 1 |
| Perez Segura, P | 1 |
| Kikuyama, S | 1 |
| Inada, T | 1 |
| Miyakita, M | 1 |
| Ogata, Y | 1 |
| Chiou, TJ | 1 |
| Tung, SL | 1 |
| Hsieh, RK | 1 |
| Wang, WS | 1 |
| Yen, CC | 1 |
| Fan, FS | 1 |
| Liu, JH | 1 |
| Chen, PM | 1 |
| Dikken, C | 1 |
| Sitzia, J | 1 |
| Hietanen, P | 1 |
| Teerenhovi, L | 1 |
| Joensuu, H | 1 |
| Rudolph, KL | 1 |
| Chang, S | 1 |
| Lee, HW | 1 |
| Blasco, M | 1 |
| Gottlieb, GJ | 1 |
| Greider, C | 1 |
| DePinho, RA | 1 |
| Hidalgo, M | 1 |
| Rinaldi, D | 1 |
| Medina, G | 1 |
| Griffin, T | 1 |
| Turner, J | 1 |
| Von Hoff, DD | 1 |
| Minamide, J | 1 |
| Aoyama, N | 1 |
| Koizumi, H | 1 |
| Yoneyama, K | 1 |
| Hoshino, S | 1 |
| Kamiya, J | 1 |
| Tamai, S | 1 |
| Kameda, Y | 1 |
| Pronk, LC | 1 |
| Vasey, P | 1 |
| Sparreboom, A | 1 |
| Reigner, B | 1 |
| Planting, AS | 1 |
| Gordon, RJ | 1 |
| Osterwalder, B | 2 |
| Verweij, J | 1 |
| Twelves, C | 1 |
| Goldwasser, F | 1 |
| Gross-Goupil, M | 1 |
| Tigaud, JM | 1 |
| Di Palma, M | 1 |
| Marceau-Suissa, J | 1 |
| Wasserman, E | 1 |
| Yovine, A | 1 |
| Misset, JL | 2 |
| Cvitkovic, E | 1 |
| Pestalozzi, BC | 1 |
| Hoff, PM | 1 |
| Ansari, R | 1 |
| Batist, G | 1 |
| Cox, J | 1 |
| Kocha, W | 1 |
| Kuperminc, M | 1 |
| Maroun, J | 1 |
| Walde, D | 1 |
| Weaver, C | 1 |
| Harrison, E | 1 |
| Burger, HU | 1 |
| Wong, AO | 1 |
| Wong, R | 1 |
| Wang, HM | 1 |
| Ng, SH | 1 |
| Wang, CH | 1 |
| Liaw, CT | 1 |
| Chen, JS | 1 |
| Yang, TS | 1 |
| Chen, IH | 1 |
| Happle, R | 1 |
| Rietschel, RL | 1 |
| Madorsky, DD | 1 |
| Hoogstraten, B | 1 |
| George, SL | 1 |
| Samal, B | 1 |
| Rivkin, SE | 1 |
| Costanzi, JJ | 1 |
| Bonnet, JD | 1 |
| Thigpen, T | 1 |
| Braine, H | 1 |
| Rosner, D | 1 |
| Nemoto, T | 1 |
| Dao, TL | 1 |
| Merrin, C | 1 |
| Etra, W | 1 |
| Wajsman, Z | 1 |
| Baumgartner, G | 1 |
| Murphy, G | 1 |
| Pouillart, P | 2 |
| Schwarzenberg, L | 2 |
| Amiel, JL | 2 |
| Mathé, G | 3 |
| Huguenin, P | 2 |
| Morin, P | 2 |
| Baron, A | 2 |
| Laparre, Ch | 2 |
| Parrot, R | 2 |
| Rees, GJ | 1 |
| Bugaighis, A | 1 |
| Anderson, G | 1 |
| Brun, B | 1 |
| Nasr, E | 1 |
| Randria, G | 1 |
| Feuilhade, F | 1 |
| Gimonet, JF | 1 |
| Le Bourgeois, JP | 1 |
| Mohapatro, SK | 1 |
| Dandapat, MC | 1 |
| Padhi, NC | 1 |
| Lindeman, GJ | 1 |
| Boyages, J | 1 |
| Driessen, C | 1 |
| Langlands, AO | 1 |
| Anderson, H | 1 |
| Scarffe, JH | 1 |
| Ranson, M | 1 |
| Kamthan, AG | 1 |
| Dougal, M | 1 |
| Russell, SA | 1 |
| Wilkinson, MJ | 1 |
| Ostick, DG | 1 |
| Cullinan, S | 1 |
| Wieand, HS | 1 |
| Schutt, AJ | 2 |
| Krook, JE | 1 |
| Foley, JF | 1 |
| Norris, BD | 1 |
| Kardinal, CG | 1 |
| Tschetter, LK | 1 |
| Barlow, JF | 1 |
| Kunii, Y | 1 |
| Kikuchi, K | 1 |
| Kasai, Y | 1 |
| Abe, O | 1 |
| Kondo, T | 1 |
| Taguchi, T | 1 |
| Hattori, T | 1 |
| Inokuchi, K | 1 |
| Komi, N | 1 |
| Ogawa, N | 1 |
| Giai, M | 1 |
| De Fabiani, E | 1 |
| Lamberto, A | 1 |
| Cortese, P | 1 |
| Giardina, G | 1 |
| Martoni, A | 1 |
| Rani, P | 1 |
| Ercolino, L | 1 |
| Canova, N | 1 |
| Pannuti, F | 1 |
| Martin-Jimenez, M | 1 |
| Gonzalez Larriba, JL | 1 |
| Sangro, B | 1 |
| Marcus, CE | 1 |
| Smith, TL | 1 |
| Bennett, JM | 1 |
| Byrne, P | 1 |
| Desai, A | 1 |
| White, C | 1 |
| DeConti, R | 1 |
| Vogel, C | 1 |
| Krementz, E | 1 |
| Muggia, F | 1 |
| Doroshow, J | 1 |
| Plotkin, D | 1 |
| Pedersen, L | 1 |
| Winton, GB | 1 |
| Salasche, SJ | 1 |
| Akazawa, S | 1 |
| Nakajima, T | 1 |
| Kitagawa, H | 1 |
| Nakagawa, T | 1 |
| Kanda, Y | 1 |
| Futatsuki, K | 1 |
| Suda, Y | 1 |
| Honda, T | 1 |
| Metz, R | 1 |
| Delgado, M | 1 |
| Keiling, R | 1 |
| Cappelaere, P | 1 |
| Armand, JP | 1 |
| Prevot, G | 1 |
| Grimbert, J | 1 |
| Levantine, A | 1 |
| Almeyda, J | 1 |
| van Eden, EB | 1 |
| Falkson, HC | 1 |
| Diem, E | 1 |
| Fritsch, P | 1 |
| Di Pietro, S | 1 |
| De Palo, GM | 1 |
| Gennari, L | 1 |
| Molinari, R | 1 |
| Damascelli, B | 1 |
| Ahmann, DL | 2 |
| Bisel, HF | 2 |
| Canellos, GP | 1 |
| Devita, VT | 1 |
| Gold, GL | 1 |
| Chabner, BA | 1 |
| Schein, PS | 1 |
| Young, RC | 1 |
| Dines, DE | 1 |
| Miller, E | 1 |
| Piro, AJ | 2 |
| Wilson, RE | 2 |
| Hall, TC | 1 |
| Aliapoulios, MA | 1 |
| Nevinny, HB | 2 |
| Moore, FD | 1 |
| Nadler, SH | 1 |
| Simister, JM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Multicenter Randomized Dble-Blind Placebo Controlled Phase III Study of the Efficacy of Xaliproden in Reducing the Neurotoxicity of the Oxaliplatin and 5-FU/LV Combination in First-Line Treatment of Patients With Metastatic Colorectal Carcinoma(MCRC)[NCT00272051] | Phase 3 | 620 participants | Interventional | 2002-07-31 | Completed | ||
| A Multicenter, Randomized Double-blind Placebo Controlled Phase III Study of the Efficacy of Xaliproden in Preventing the Neurotoxicity of Oxaliplatin in First-line Treatment of Patients With Metastatic Colorectal Cancer Treated With Oxaliplatin / 5-FU/LV[NCT00305188] | Phase 3 | 879 participants (Actual) | Interventional | 2005-12-31 | Completed | ||
| PACCE: A Randomized, Open-Label, Controlled, Clinical Trial of Chemotherapy and Bevacizumab With and Without Panitumumab in the First-Line Treatment of Subjects With Metastatic Colorectal Cancer[NCT00115765] | Phase 3 | 1,053 participants (Actual) | Interventional | 2005-06-01 | Completed | ||
| A Randomised, Double-blind, Multicentre Phase II/III Study to Compare the Efficacy of Cediranib (RECENTIN™, AZD2171) in Combination With 5-fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX), to the Efficacy of Bevacizumab in Combination With FOLFOX in Pat[NCT00384176] | Phase 2/Phase 3 | 1,814 participants (Actual) | Interventional | 2006-08-30 | Completed | ||
| A Randomized, Multicenter, Phase 3 Study to Compare the Efficacy of Panitumumab in Combination With Oxaliplatin/ 5-fluorouracil/ Leucovorin to the Efficacy of Oxaliplatin/ 5-fluorouracil/ Leucovorin Alone in Patients With Previously Untreated Metastatic C[NCT00364013] | Phase 3 | 1,183 participants (Actual) | Interventional | 2006-08-01 | Completed | ||
| A Randomized Controlled Trial to Evaluate Effectiveness of Cooling Cap to Prevent Permanent Chemotherapy-induced Alopecia Among Breast Cancer Patients[NCT04678544] | 170 participants (Actual) | Interventional | 2020-12-23 | Completed | |||
| A Prospective, Single-arm, Phase II Study of Adelbelimab Combined With Carboplatin and Nab-paclitaxel in Neoadjuvant Therapy for Patients With Resectable Locally Advanced Squamous Cell Carcinoma of the Head and Neck[NCT06016413] | Phase 2 | 30 participants (Anticipated) | Interventional | 2023-09-01 | Not yet recruiting | ||
| Study of TPF (Docetaxel, Cisplatin, 5-fluorouracil) Induction Chemotherapy Followed by Surgery and Radiotherapy in Patients With Locally Advanced and Resectable Oral Squamous Cell Carcinoma[NCT01542931] | Phase 2/Phase 3 | 256 participants (Actual) | Interventional | 2008-01-31 | Completed | ||
| Phase 1 Study of Postoperative Capecitabine With Concurrent Radiation in Elderly With Stage II/III Rectal Cancer[NCT01268943] | Phase 1 | 18 participants (Actual) | Interventional | 2010-11-30 | Completed | ||
| A Pilot Study Using Neoadjuvant Proton Beam Radiation Therapy and Chemotherapy for Marginally Resectable Carcinoma of the Pancreas[NCT00763516] | 8 participants (Actual) | Interventional | 2009-02-28 | Completed | |||
| Randomized Trial to Evaluate Therapeutic Gain by Changing Chemoradiotherapy From Concurrent-adjuvant to Induction-concurrent Sequence, and Radiotherapy From Conventional to Accelerated Fractionation for Advanced Nasopharyngeal Carcinoma[NCT00379262] | Phase 3 | 803 participants (Actual) | Interventional | 2006-09-30 | Completed | ||
| A Study Using Photon/Proton Beam Radiation Therapy and Chemotherapy for Unresectable Carcinoma of the Pancreas[NCT00685763] | 13 participants (Actual) | Interventional | 2008-03-31 | Completed | |||
| A Pilot Study- Prevention of Capecitabine Induced Hand and Foot Syndrome[NCT01291628] | 10 participants (Anticipated) | Interventional | 2012-01-31 | Not yet recruiting | |||
| Randomized Open-label Trial of Dose Dense, Fixed Dose Capecitabine Compared to Standard Dose Capecitabine in Metastatic Breast Cancer and Advanced/Metastatic Gastrointestinal Cancers.[NCT02595320] | Phase 2 | 200 participants (Actual) | Interventional | 2015-10-05 | Active, not recruiting | ||
| Phase I Study of Preoperative Concurrent Chemo-radiation With Capecitabine in Elderly Rectal Cancer Patients[NCT01584544] | Phase 1 | 24 participants (Actual) | Interventional | 2011-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Best overall response of complete or partial response within irinotecan stratum (NCT00115765)
Timeframe: Overall Study
| Intervention | Participant (Number) |
|---|---|
| Irinotecan and Bevacizumab Plus Panitumumab | 49 |
| Irinotecan and Bevacizumab Without Panitumumab | 46 |
Best overall response of complete or partial response in participants treated with irinotecan and having a mutant Kirsten Rat Sarcoma Virus Oncogene (KRAS) (NCT00115765)
Timeframe: Overall Study
| Intervention | Participant (Number) |
|---|---|
| Irinotecan and Bevacizumab Plus Panitumumab | 14 |
| Irinotecan and Bevacizumab Without Panitumumab | 15 |
Best overall response of complete or partial response within oxaliplatin stratum (NCT00115765)
Timeframe: Overall study
| Intervention | Participant (Number) |
|---|---|
| Oxaliplatin and Bevacizumab Plus Panitumumab | 190 |
| Oxaliplatin and Bevacizumab Without Panitumumab | 196 |
Best overall response of complete or partial response in participants treated with irinotecan and having a wild-type Kirsten Rat Sarcoma Virus Oncogene (KRAS) (NCT00115765)
Timeframe: Overall Study
| Intervention | Participant (Number) |
|---|---|
| Irinotecan and Bevacizumab Plus Panitumumab | 31 |
| Irinotecan and Bevacizumab Without Panitumumab | 28 |
Objective tumor response (complete or partial) rate through week 12 based on central review in the Irinotecan stratum (NCT00115765)
Timeframe: Overall Study
| Intervention | Participant (Number) |
|---|---|
| Irinotecan and Bevacizumab Plus Panitumumab | 29 |
| Irinotecan and Bevacizumab Without Panitumumab | 27 |
Incidence of mortality from any cause in groups treated with Irinotecan. Incidence is provided in lieu of the median time to death since the median or its measure of dispersion was not estimable for at least one treatment arm. (NCT00115765)
Timeframe: Overall study
| Intervention | Participant (Number) |
|---|---|
| Irinotecan and Bevacizumab Plus Panitumumab | 26 |
| Irinotecan and Bevacizumab Without Panitumumab | 18 |
Kaplan-Meier estimate of the median time from randomization to death from any cause in groups treated with Oxaliplatin and having a mutant Kirsten Rat Sarcoma Virus Oncogene (KRAS). Since the measure of dispersion could not be estimated for at least one treatment arm, participant incidence is provided in lieu of the median. (NCT00115765)
Timeframe: Overall Study
| Intervention | Participant (Number) |
|---|---|
| Oxaliplatin and Bevacizumab Plus Panitumumab | 47 |
| Oxaliplatin and Bevacizumab Without Panitumumab | 45 |
Kaplan-Meier estimate of the median time from randomization to death from any cause in groups treated with Oxaliplatin (NCT00115765)
Timeframe: Overall study
| Intervention | Month (Median) |
|---|---|
| Oxaliplatin and Bevacizumab Plus Panitumumab | 19.4 |
| Oxaliplatin and Bevacizumab Without Panitumumab | 24.5 |
Kaplan-Meier estimate of the median time from randomization to death from any cause in groups treated with Oxaliplatin and having a wild-type Kirsten Rat Sarcoma Virus Oncogene (KRAS). Since the measure of dispersion could not be estimated for at least one treatment arm, participant incidence is provided in lieu of the median (NCT00115765)
Timeframe: Overall Study
| Intervention | Participant (Number) |
|---|---|
| Oxaliplatin and Bevacizumab Plus Panitumumab | 71 |
| Oxaliplatin and Bevacizumab Without Panitumumab | 46 |
Kaplan-Meier estimate of the median time from randomization to death from any cause or first observed disease progression (NCT00115765)
Timeframe: Overall Study
| Intervention | Month (Median) |
|---|---|
| Irinotecan and Bevacizumab Plus Panitumumab | 10.1 |
| Irinotecan and Bevacizumab Without Panitumumab | 11.7 |
Kaplan-Meier estimate of the median time from randomization to death from any cause or first observed disease progression in groups treated with oxaliplatin and having a mutant Kirsten Rat Sarcoma Virus Oncogene (KRAS) (NCT00115765)
Timeframe: Overall Study
| Intervention | Month (Median) |
|---|---|
| Oxaliplatin and Bevacizumab Plus Panitumumab | 10.4 |
| Oxaliplatin and Bevacizumab Without Panitumumab | 11.0 |
Kaplan-Meier estimate of the median time from randomization to death from any cause or first observed disease progression (NCT00115765)
Timeframe: Overall study
| Intervention | Month (Median) |
|---|---|
| Oxaliplatin and Bevacizumab Plus Panitumumab | 10.0 |
| Oxaliplatin and Bevacizumab Without Panitumumab | 11.4 |
Kaplan-Meier estimate of the median time from randomization to death from any cause or first observed disease progression in groups treated with oxaliplatin and having a wild-type Kirsten Rat Sarcoma Virus Oncogene (KRAS) (NCT00115765)
Timeframe: Overall Study
| Intervention | Month (Median) |
|---|---|
| Oxaliplatin and Bevacizumab Plus Panitumumab | 9.8 |
| Oxaliplatin and Bevacizumab Without Panitumumab | 11.5 |
Kaplan-Meier estimate of the median time from randomization to disease progression or death due to disease progression within the irinotecan stratum (NCT00115765)
Timeframe: Overall Study
| Intervention | Month (Median) |
|---|---|
| Irinotecan and Bevacizumab Plus Panitumumab | 11.1 |
| Irinotecan and Bevacizumab Without Panitumumab | 11.9 |
Kaplan-Meier estimate of the median time from randomization to disease progression or death due to disease progression within the oxaliplatin stratum (NCT00115765)
Timeframe: Overall Study
| Intervention | Month (Median) |
|---|---|
| Oxaliplatin and Bevacizumab Plus Panitumumab | 10.8 |
| Oxaliplatin and Bevacizumab Without Panitumumab | 11.4 |
Kaplan-Meier estimate of the median time from randomization to the date the decision was made to discontinue treatment for a reason other than a complete response to treatment within the irinotecan stratum (NCT00115765)
Timeframe: Overall Study
| Intervention | Month (Median) |
|---|---|
| Irinotecan and Bevacizumab Plus Panitumumab | 6.6 |
| Irinotecan and Bevacizumab Without Panitumumab | 6.0 |
Kaplan-Meier estimate of the median time from randomization to the date the decision was made to discontinue treatment for a reason other than a complete response to treatment within the oxaliplatin stratum. (NCT00115765)
Timeframe: Overall study
| Intervention | Month (Median) |
|---|---|
| Oxaliplatin and Bevacizumab Plus Panitumumab | 5.7 |
| Oxaliplatin and Bevacizumab Without Panitumumab | 5.9 |
Duration of Response is calculated as the time from the first recording of CR/PR until the patient progresses, regardless of whether the patient was still taking study medication. Only confirmed responses are included in the calculation. For patients who had not progressed, the end date used in the calculation of duration of response is the data cut-off date of 15th November 2009. (NCT00384176)
Timeframe: Up until data cut-off date of 15/11/2007
| Intervention | Months (Median) |
|---|---|
| Cediranib 20 mg | 8.6 |
| Bevacizumab 5 mg/kg | 9.6 |
"Objective response rate is Complete Response (CR) + Partial Response (PR) as defined below:~CR = Disappearance of all target lesions. PR = At least a 30% decrease in the sum of longest diameters (LDs) of target lesions, taking as reference the baseline sum of LDs." (NCT00384176)
Timeframe: Up until data cut-off
| Intervention | Participants (Number) |
|---|---|
| Cediranib 20 mg | 328 |
| Bevacizumab 5 mg/kg | 337 |
Number of months from randomisation to the date of death from any cause (NCT00384176)
Timeframe: Randomisation until data cut-off
| Intervention | Months (Median) |
|---|---|
| Cediranib 20 mg | 22.8 |
| Bevacizumab 5 mg/kg | 21.3 |
Percentage change in tumour size from baseline to first RECIST assessment (Week 8) ((Week 8 - baseline)/baseline)*100 (NCT00384176)
Timeframe: Baseline to Week 8
| Intervention | Percentage change in tumour size (Mean) |
|---|---|
| Cediranib 20 mg | -23.2 |
| Bevacizumab 5 mg/kg | -22.1 |
Progression is defined as the number of months from randomisation until progressive disease based on RECIST (progression of target lesions, clear progression of existing non-target lesions or the appearance of one or more new lesions) or death in the absence of progression. (NCT00384176)
Timeframe: Baseline then at Weeks 8, 16, 24 and then every 12 weeks until progression
| Intervention | Months (Median) |
|---|---|
| Cediranib 20 mg | 9.9 |
| Bevacizumab 5 mg/kg | 10.3 |
Time to worsening of symptoms, as measured by the FACT colorectal symptom index (FCSI), will be defined as the time when a sustained clinically important deterioration in the total score from the FCSI has been recorded. (NCT00384176)
Timeframe: Baseline through to data cut-off
| Intervention | Days (Median) |
|---|---|
| Cediranib 20 mg | 170 |
| Bevacizumab 5 mg/kg | 245 |
Duration of response was calculated only for those participants with a confirmed CR or PR, as the time from the first CR or PR (subsequently confirmed within no less than 4 weeks) to first observed disease progression per modified RECIST criteria, based on a blinded central review. (NCT00364013)
Timeframe: Every 8 weeks until disease progression up to the data cut-off date of 30 September 2008; Maximum follow-up time was 109 weeks.
| Intervention | months (Median) |
|---|---|
| Wild-type KRAS - FOLFOX + Panitumumab | 11.1 |
| Wild-type KRAS - FOLFOX | 8.8 |
| Mutant KRAS - FOLFOX + Panitumumab | 7.4 |
| Mutant KRAS - FOLFOX | 8.0 |
The definition of overall survival is the time from randomization to death; participants who were alive at the analysis data cutoff were censored at their last contact date. (NCT00364013)
Timeframe: From randomization until the data cutoff date of 28 August 2009. Maximum time on follow-up was 153 weeks.
| Intervention | months (Median) |
|---|---|
| Wild-type KRAS - FOLFOX + Panitumumab | 23.9 |
| Wild-type KRAS - FOLFOX | 19.7 |
| Mutant KRAS - FOLFOX + Panitumumab | 15.5 |
| Mutant KRAS - FOLFOX | 19.3 |
Participants were evaluated for tumor response per the modified Response Evaluation Criteria in Solid Tumors (RECIST) criteria every 8 weeks until disease progression. Objective response by central radiological assessment was defined as the incidence of either a confirmed complete or partial response (CR or PR) while on the first-line treatment, as determined by blinded independent central review and confirmed no less than 4-weeks after the criteria for response are first met. CR: Disappearance of all target and non-target lesions and no new lesions. PR: At least a 30% decrease in the sum of the longest diameter of target lesions and no progression of non-target or no new lesions, or, disappearance of all target lesions and the persistence of ≥ 1 non-target lesion not qualifying for either CR or progressive disease. Participants without a post-baseline assessment were considered non-responders. (NCT00364013)
Timeframe: Every 8 weeks until disease progression up to the data cut-off date of 30 September 2008; Maximum follow-up time was 109 weeks.
| Intervention | percentage of participants (Number) |
|---|---|
| Wild-type KRAS - FOLFOX + Panitumumab | 55.21 |
| Wild-type KRAS - FOLFOX | 47.68 |
| Mutant KRAS - FOLFOX + Panitumumab | 39.53 |
| Mutant KRAS - FOLFOX | 40.28 |
Progression-free survival (PFS), assessed by central radiological assessment, was defined as the time from randomization to disease progression per modified response evaluation criteria in solid tumors (RECIST) criteria or death. Participants who were alive but did not meet criteria for progression by the data cutoff date were censored at their last evaluable disease assessment date. Progressive disease is defined as a ≥ 20% increase in the size of target lesions or unequivocal progression of existing non-target lesions or any new lesions. (NCT00364013)
Timeframe: From randomization until the data cutoff date of 30 September 2008. Maximum follow-up time was 109 weeks.
| Intervention | months (Median) |
|---|---|
| Wild-type KRAS - FOLFOX + Panitumumab | 9.6 |
| Wild-type KRAS - FOLFOX | 8.0 |
| Mutant KRAS - FOLFOX + Panitumumab | 7.3 |
| Mutant KRAS - FOLFOX | 8.8 |
Time to progression was defined as time from randomization date to date of disease progression per the modified RECIST criteria. (NCT00364013)
Timeframe: From randomization until the data cut-off date of 30 September 2008; Maximum follow-up time was 109 weeks.
| Intervention | months (Median) |
|---|---|
| Wild-type KRAS - FOLFOX + Panitumumab | 10.8 |
| Wild-type KRAS - FOLFOX | 9.2 |
| Mutant KRAS - FOLFOX + Panitumumab | 7.5 |
| Mutant KRAS - FOLFOX | 9.0 |
"A serious adverse event (SAE) is defined as an AE that • is fatal • is life threatening • requires in-patient hospitalization or prolongation of existing hospitalization • results in persistent or significant disability/incapacity • is a congenital anomaly/birth defect • other significant medical hazard. The relationship of the adverse event to the study treatment was assessed by the Investigator by means of the question: Is there a reasonable possibility that the event may have been caused by the study treatment?" (NCT00364013)
Timeframe: From randomization until the data cut-off date of 28 August 2009; Maximum time on follow-up was 153 weeks.
| Intervention | participants (Number) | |||||
|---|---|---|---|---|---|---|
| Any adverse event | Serious adverse event | Leading to discontinuation of any study drug | Treatment-related adverse event (TRAE) | Serious treatment-related adverse event | TRAE leading to discontinuation of any study drug | |
| FOLFOX + Panitumumab | 583 | 262 | 136 | 581 | 162 | 117 |
| FOLFOX Alone | 579 | 198 | 84 | 565 | 89 | 63 |
dose related toxicity is defined as follows:1. WBC damage >= grade 3; granular cell decrease >= grade 3; hemoglobin >= grade 2; platelet >= grade 2;SGPT/SGOT elevation >= grade 2; ALP >= grade 2; GGT >= grade 2; Tbil >= grade 2;renal function damage: BUN/Cr elevation >= grade 2;Non-gradular cell decreased fever >= grade 2;nausea/vomiting >= grade 2; fatigue >= grade 3; weight loss >= grade 3;gastritis >= grade 3; dairrea >= grade 3; abdominal pain >= grade 3; pancreatitis >= grade 2; upper gastrointestinal bleeding >= grade 2;other toxic reaction >= grade 3;KPS < 50 during the treatment (NCT01268943)
Timeframe: up to 9 weeks
| Intervention | event (Number) |
|---|---|
| 1000mg | 1 |
| 1200mg | 0 |
| 1400mg | 0 |
| 1500mg | 3 |
(NCT00685763)
Timeframe: 1 year following the completion of radiation therapy
| Intervention | participants (Number) |
|---|---|
| Proton Radiation and Chemotherapy | 0 |
Dose related toxicity is defined as follows:1. luecopenia > grade 2; granular cell decrease > grade 2; anemia > grade 1; platelet > grade 1;SGPT/SGOT elevation > grade 1; ALP > grade 1; GGT > grade 1; Tbil > grade 1;renal function damag > grade 2;Non-gradular cell decreased fever > grade 1;nausea/vomiting > grade 1; fatigue > grade 2; weight loss > grade 2;gastritis > grade 2; dairrea > grade 2; abdominal pain > grade 2; upper gastrointestinal bleeding > grade 1;other toxic reaction > grade 2;KPS < 50 during the treatment (NCT01584544)
Timeframe: up to 7 weeks from start of the treatment
| Intervention | participants (Number) |
|---|---|
| 1000mg | 0 |
| 1200mg | 1 |
| 1350mg | 1 |
| 1500mg | 0 |
| 1650mg | 1 |
9 reviews available for fluorouracil and Alopecia Cicatrisata
| Article | Year |
|---|---|
Topics: Alopecia; Anilides; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Basal Cel | 2018 |
Raltitrexed-based chemotherapy for advanced colorectal cancer.
Topics: Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Asthenia; Chemical and Drug Induce | 2014 |
Irinotecan chemotherapy combined with fluoropyrimidines versus irinotecan alone for overall survival and progression-free survival in patients with advanced and/or metastatic colorectal cancer.
Topics: Alopecia; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combine | 2016 |
Capecitabine-based combination therapy for breast cancer: implications for nurses.
Topics: Alopecia; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bone Marr | 2009 |
Single-agent irinotecan or FOLFIRI as second-line chemotherapy for advanced colorectal cancer; results of a randomised phase II study (DaVINCI) and meta-analysis [corrected].
Topics: Adult; Aged; Aged, 80 and over; Alopecia; Antineoplastic Agents, Phytogenic; Antineoplastic Combined | 2011 |
Management of adverse events and other practical considerations in patients receiving capecitabine (Xeloda).
Topics: Alopecia; Ambulatory Care; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Colonic | 2004 |
Scalp cooling has no place in the prevention of alopecia in adjuvant chemotherapy for breast cancer.
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherap | 1994 |
Drug reactions. XXIV. Cutaneous reactions to cytostatic agents.
Topics: Alopecia; Aminopterin; Antineoplastic Agents; Asparaginase; Azathioprine; Bleomycin; Busulfan; Chlor | 1974 |
The metabolism and pharmacology of 5-fluorouracil.
Topics: Adenocarcinoma; Alopecia; Animals; Breast Neoplasms; Carbon Isotopes; Cell Division; Chromosome Aber | 1971 |
44 trials available for fluorouracil and Alopecia Cicatrisata
| Article | Year |
|---|---|
Minimal added value of wetting hair before scalp cooling to prevent chemotherapy-induced alopecia in cancer patients - results from the Dutch Scalp Cooling Registry.
Topics: Alopecia; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; C | 2023 |
Prolonging the duration of post-infusion scalp cooling in the prevention of anthracycline-induced alopecia: a randomised trial in patients with breast cancer treated with adjuvant chemotherapy.
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherap | 2019 |
Efficacy of nimotuzumab combined with docetaxel-cisplatin-fluorouracil regimen in treatment of advanced oral carcinoma.
Topics: Aged; Aged, 80 and over; Alopecia; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemot | 2014 |
One year of adjuvant tamoxifen compared with chemotherapy and tamoxifen in postmenopausal patients with stage II breast cancer.
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherap | 2013 |
Phase I dose escalation study with irinotecan, capecitabine, epirubicin, and granulocyte colony-stimulating factor support for patients with solid malignancies.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Pr | 2008 |
Single-agent irinotecan or FOLFIRI as second-line chemotherapy for advanced colorectal cancer; results of a randomised phase II study (DaVINCI) and meta-analysis [corrected].
Topics: Adult; Aged; Aged, 80 and over; Alopecia; Antineoplastic Agents, Phytogenic; Antineoplastic Combined | 2011 |
The efficacy and safety of neoadjuvant chemotherapy +/- letrozole in postmenopausal women with locally advanced breast cancer: a randomized phase III clinical trial.
Topics: Aged; Aged, 80 and over; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; | 2012 |
Randomized phase III trial of induction chemotherapy with docetaxel, cisplatin, and fluorouracil followed by surgery versus up-front surgery in locally advanced resectable oral squamous cell carcinoma.
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cis | 2013 |
Randomized phase III trial of induction chemotherapy with docetaxel, cisplatin, and fluorouracil followed by surgery versus up-front surgery in locally advanced resectable oral squamous cell carcinoma.
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cis | 2013 |
Randomized phase III trial of induction chemotherapy with docetaxel, cisplatin, and fluorouracil followed by surgery versus up-front surgery in locally advanced resectable oral squamous cell carcinoma.
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cis | 2013 |
Randomized phase III trial of induction chemotherapy with docetaxel, cisplatin, and fluorouracil followed by surgery versus up-front surgery in locally advanced resectable oral squamous cell carcinoma.
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cis | 2013 |
Irinotecan (CPT-11) in metastatic colorectal cancer patients resistant to 5-fluorouracil (5-FU): a phase II study.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Alopecia; Camptothecin; Chemotherapy, Adjuvant; Colorectal | 2003 |
Phase I evaluation of continuous 5-fluorouracil infusion followed by weekly paclitaxel in patients with advanced or recurrent gastric cancer.
Topics: Adult; Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relatio | 2005 |
'Atrophic telogen effluvium' from cytotoxic drugs and a randomized controlled trial to investigate the possible protective effect of pretreatment with a topical vitamin D analogue in humans.
Topics: Administration, Topical; Adult; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Breast Neo | 2005 |
A randomized trial between two neoadjuvant chemotherapy protocols: CDDP + 5-FU versus CDDP + VP16 in advanced cancer of the head and neck.
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Diarrhea; Etoposid | 2005 |
[Clinical evaluation of DLF, CLF and DFM regimens based on platinum compound plus 5-fluorouracil for treatment of advanced esophageal carcinoma].
Topics: Adenocarcinoma; Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Ca | 2006 |
[Phase I/II clinical trial of induction chemotherapy with nedaplatin (CDGP), docetaxel (DOC) and 5-fluorouracil (5-FU) for squamous cell carcinoma of head and neck].
Topics: Adult; Aged; Alopecia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2007 |
A phase II study of trastuzumab and capecitabine for patients with HER2-overexpressing metastatic breast cancer: Japan Breast Cancer Research Network (JBCRN) 00 Trial.
Topics: Administration, Oral; Adult; Aged; Alopecia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humaniz | 2008 |
A randomized phase III multicenter trial comparing irinotecan in combination with the Nordic bolus 5-FU and folinic acid schedule or the bolus/infused de Gramont schedule (Lv5FU2) in patients with metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; | 2008 |
Thymidine phosphorylase expression is associated with time to progression in patients receiving low-dose, docetaxel-modulated capecitabine for metastatic breast cancer.
Topics: Administration, Oral; Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Biomark | 2008 |
The value of two combined chemoradiotherapy approaches in the treatment of inoperable esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Ca | 1984 |
Chemoimmunotherapy for metastatic breast cancer with 5-fluorouracil, adriamycin, cyclophosphamide, methotrexate, L-asparaginase, Corynebacterium parvum, and Pseudomonas vaccine.
Topics: Alopecia; Antineoplastic Agents; Asparaginase; Bacterial Vaccines; Blood Cell Count; Breast Neoplasm | 1980 |
Impact of protracted venous infusion fluorouracil with or without interferon alfa-2b on tumor response, survival, and quality of life in advanced colorectal cancer.
Topics: Adolescent; Adult; Aged; Alopecia; Chi-Square Distribution; Colorectal Neoplasms; Combined Modality | 1995 |
Scalp cooling has no place in the prevention of alopecia in adjuvant chemotherapy for breast cancer.
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherap | 1994 |
A randomized phase II study comparing sequential versus simultaneous chemo-radiotherapy in patients with unresectable locally advanced squamous cell cancer of the head and neck.
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chi | 1994 |
[Sequential methotrexate/5-fluorouracil therapy with 5'-deoxy-5-fluorouridine against advanced gastric cancer: comparison between bolus injection and drip infusion of 5-fluorouracil administration. Hirosaki Cooperative Study Group for Cancer Chemotherapy]
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Anorexia; Antineoplastic Combined Ch | 1994 |
Adjuvant cyclophosphamide, methotrexate, and fluorouracil versus fluorouracil, epirubicin, and cyclophosphamide chemotherapy in premenopausal women with axillary node-positive operable breast cancer: results of a randomized trial. The International Collab
Topics: Adult; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Axilla; Breast Neoplasms; Chemother | 1996 |
A randomized trial of minoxidil in chemotherapy-induced alopecia.
Topics: Administration, Cutaneous; Adult; Alopecia; Antibiotics, Antineoplastic; Antimetabolites, Antineopla | 1996 |
Neoadjuvant therapy with cisplatin/fluorouracil vs cisplatin/UFT in locally advanced squamous cell head and neck cancer.
Topics: Adult; Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous C | 1997 |
Phase II study of 5-fluorouracil, pirarubicin and low-dose consecutive administration of cisplatin for advanced and recurrent gastric cancer.
Topics: Adult; Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubici | 1998 |
Phase II study of the modified regimen of etoposide, leucovorin and 5-fluorouracil for patients with advanced gastric cancer.
Topics: Adult; Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Diarrhea; Drug Admini | 1998 |
A phase I trial of topical topitriol (calcitriol, 1,25-dihydroxyvitamin D3) to prevent chemotherapy-induced alopecia.
Topics: Administration, Topical; Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Brea | 1999 |
Postoperative complications in patients of esophageal cancer after neoadjuvant chemotherapy.
Topics: Alopecia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin; Esophage | 1999 |
A phase I and pharmacokinetic study of the combination of capecitabine and docetaxel in patients with advanced solid tumours.
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Asthenia; Biotransformation; | 2000 |
Dose escalation of CPT-11 in combination with oxaliplatin using an every two weeks schedule: a phase I study in advanced gastrointestinal cancer patients.
Topics: Adult; Aged; Alopecia; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protoco | 2000 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Intra-arterial plus i.v. chemotherapy for advanced bulky squamous cell carcinoma of the buccal mucosa.
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cis | 2001 |
Combination chemotherapy and adriamycin in patients with advanced breast cancer. A Southwest Oncology Group study.
Topics: Alopecia; Antineoplastic Agents; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Drug Evaluation; D | 1976 |
Chemotherapy of advanced carcinoma of the prostate with 5-fluorouracil, cyclophosphamide and adriamycin.
Topics: Adenocarcinoma; Aged; Alopecia; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; Drug Evalua | 1976 |
A prospective randomized trial comparing epirubicin monochemotherapy to two fluorouracil, cyclophosphamide, and epirubicin regimens differing in epirubicin dose in advanced breast cancer patients. The French Epirubicin Study Group.
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neopla | 1991 |
A phase III trial on the therapy of advanced pancreatic carcinoma. Evaluations of the Mallinson regimen and combined 5-fluorouracil, doxorubicin, and cisplatin.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Alopecia; Antineoplastic Combined Chemotherapy Proto | 1990 |
[Cooperative study of surgical adjuvant chemotherapy of colorectal cancer (first report): Investigation of background factors and adverse effects. Cooperative Study Group of Surgical Adjuvant Chemotherapy of Colorectal Cancer in Japan].
Topics: Alopecia; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Doxorubicin; Fluorourac | 1987 |
Failure of high-dose tocopherol to prevent alopecia induced by doxorubicin.
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Tr | 1986 |
Immediate and long-term toxicity of adjuvant chemotherapy regimens containing doxorubicin in trials at M.D. Anderson Hospital and Tumor Institute.
Topics: Adult; Alopecia; Amenorrhea; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Breas | 1986 |
A randomized multicenter trial of cyclophosphamide, Novantrone and 5-fluorouracil (CNF) versus cyclophosphamide, Adriamycin and 5-fluorouracil (CAF) in patients with metastatic breast cancer.
Topics: Adult; Aged; Alopecia; Anthraquinones; Breast Neoplasms; Clinical Trials as Topic; Cyclophosphamide; | 1985 |
Fluorouracil, imidazole carboxamide dimethyl triazeno, vincristine, and bis-chloroethyl nitrosourea in colon cancer.
Topics: Alopecia; Amides; Antineoplastic Agents; Carmustine; Clinical Trials as Topic; Colonic Neoplasms; Dr | 1974 |
A controlled evaluation of 5-fluorouracil utilizing a single injection technique.
Topics: Adenocarcinoma; Alopecia; Evaluation Studies as Topic; Fluorouracil; Gastrointestinal Diseases; Huma | 1974 |
67 other studies available for fluorouracil and Alopecia Cicatrisata
| Article | Year |
|---|---|
Colorectal cancer chemotherapy: can sex-specific disparities impact on drug toxicities?
Topics: Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug-Related | 2022 |
Acquired unilateral alopecia after arterial infusion chemotherapy in a recurrent nasopharyngeal carcinoma.
Topics: Adult; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Epistaxis; Fluorouracil; | 2022 |
Prospective observational study of chemotherapy-induced alopecia after sequential FEC + taxane and the effects of age in breast cancer patients.
Topics: Adult; Age Factors; Aged; Alopecia; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Prot | 2021 |
Toxicity profile of taxanes in Tunisian cancer patients: A retrospective study of 90 cases.
Topics: Adult; Aged; Alopecia; Antineoplastic Agents; Breast Neoplasms; Cisplatin; Digestive System Diseases | 2021 |
Chemotherapy-induced alopecia: A novel observation.
Topics: Alopecia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Dermos | 2019 |
Impact of Sex on Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer: Pooled Analysis of 5 Randomized Trials.
Topics: Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy-Induced Febrile | 2019 |
Impact of Sex on Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer: Pooled Analysis of 5 Randomized Trials.
Topics: Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy-Induced Febrile | 2019 |
Impact of Sex on Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer: Pooled Analysis of 5 Randomized Trials.
Topics: Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy-Induced Febrile | 2019 |
Impact of Sex on Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer: Pooled Analysis of 5 Randomized Trials.
Topics: Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy-Induced Febrile | 2019 |
Impact of Sex on Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer: Pooled Analysis of 5 Randomized Trials.
Topics: Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy-Induced Febrile | 2019 |
Impact of Sex on Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer: Pooled Analysis of 5 Randomized Trials.
Topics: Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy-Induced Febrile | 2019 |
Impact of Sex on Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer: Pooled Analysis of 5 Randomized Trials.
Topics: Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy-Induced Febrile | 2019 |
Impact of Sex on Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer: Pooled Analysis of 5 Randomized Trials.
Topics: Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy-Induced Febrile | 2019 |
Impact of Sex on Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer: Pooled Analysis of 5 Randomized Trials.
Topics: Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy-Induced Febrile | 2019 |
Impact of Sex on Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer: Pooled Analysis of 5 Randomized Trials.
Topics: Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy-Induced Febrile | 2019 |
Impact of Sex on Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer: Pooled Analysis of 5 Randomized Trials.
Topics: Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy-Induced Febrile | 2019 |
Impact of Sex on Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer: Pooled Analysis of 5 Randomized Trials.
Topics: Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy-Induced Febrile | 2019 |
Impact of Sex on Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer: Pooled Analysis of 5 Randomized Trials.
Topics: Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy-Induced Febrile | 2019 |
Impact of Sex on Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer: Pooled Analysis of 5 Randomized Trials.
Topics: Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy-Induced Febrile | 2019 |
Impact of Sex on Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer: Pooled Analysis of 5 Randomized Trials.
Topics: Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy-Induced Febrile | 2019 |
Impact of Sex on Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer: Pooled Analysis of 5 Randomized Trials.
Topics: Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy-Induced Febrile | 2019 |
Impact of Sex on Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer: Pooled Analysis of 5 Randomized Trials.
Topics: Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy-Induced Febrile | 2019 |
Impact of Sex on Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer: Pooled Analysis of 5 Randomized Trials.
Topics: Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy-Induced Febrile | 2019 |
Impact of Sex on Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer: Pooled Analysis of 5 Randomized Trials.
Topics: Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy-Induced Febrile | 2019 |
Impact of Sex on Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer: Pooled Analysis of 5 Randomized Trials.
Topics: Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy-Induced Febrile | 2019 |
Impact of Sex on Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer: Pooled Analysis of 5 Randomized Trials.
Topics: Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy-Induced Febrile | 2019 |
Impact of Sex on Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer: Pooled Analysis of 5 Randomized Trials.
Topics: Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy-Induced Febrile | 2019 |
Impact of Sex on Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer: Pooled Analysis of 5 Randomized Trials.
Topics: Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy-Induced Febrile | 2019 |
Impact of Sex on Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer: Pooled Analysis of 5 Randomized Trials.
Topics: Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy-Induced Febrile | 2019 |
Impact of Sex on Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer: Pooled Analysis of 5 Randomized Trials.
Topics: Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy-Induced Febrile | 2019 |
Comparative assessment of skin and subcutaneous toxicity in patients of advanced colorectal carcinoma treated with different schedules of FOLFOX.
Topics: Adult; Aged; Aged, 80 and over; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Colorectal | 2013 |
Results of scalp cooling during anthracycline containing chemotherapy depend on scalp skin temperature.
Topics: Adult; Aged; Alopecia; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neopla | 2016 |
Permanent scalp alopecia related to breast cancer chemotherapy by sequential fluorouracil/epirubicin/cyclophosphamide (FEC) and docetaxel: a prospective study of 20 patients.
Topics: Adult; Aged; Alopecia; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast | 2012 |
[Cisplatin, 5-fluorouracil, and high-dose leucovorin for advanced esophageal cancer].
Topics: Aged; Aged, 80 and over; Alopecia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Bone Ma | 2003 |
Lethal 5-fluorouracil toxicity associated with a novel mutation in the dihydropyrimidine dehydrogenase gene.
Topics: Adult; Alopecia; Anemia; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Proto | 2003 |
Severe 5-fluorouracil toxicity associated with a marked alteration of pharmacokinetics of 5-fluorouracil and its catabolite 5-fluoro-5,6-dihydrouracil: a case report.
Topics: Alopecia; Antimetabolites, Antineoplastic; Area Under Curve; Diarrhea; Drug Eruptions; Female; Fever | 2002 |
Prognostic factor analysis in advanced gastric cancer patients treated with hydroxyurea, leucovorin, 5-fluorouracil, and cisplatin (HLFP regimen).
Topics: Adenocarcinoma; Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, T | 2003 |
CURRENT STATUS OF 5-FLUOROURACIL THERAPY IN FAR-ADVANCED NEOPLASTIC DISEASE.
Topics: Alopecia; Chlorpromazine; Diarrhea; Erythema; Fluorouracil; Leukopenia; Nausea; Neoplasms; Thrombocy | 1964 |
FLUORINATED PYRIMIDINE THERAPY OF ADVANCED GASTROINTESTINAL CANCER.
Topics: Alopecia; Colonic Neoplasms; Drug Eruptions; Esophagitis; Fluorouracil; Gallbladder Neoplasms; Human | 1964 |
TREATMENT OF ADVANCED CANCER WITH 5-FLUOROURACIL.
Topics: Alopecia; Breast Neoplasms; Colonic Neoplasms; Diarrhea; Drug Eruptions; Fluorouracil; Humans; Leuko | 1964 |
SKIN CHANGES CAUSED BY CANCER CHEMOTHERAPY.
Topics: Alopecia; Anti-Bacterial Agents; Antibiotics, Antitubercular; Antineoplastic Agents; Cyclophosphamid | 1964 |
A LESS TOXIC FLUOROURACIL DOSAGE SCHEDULE.
Topics: Alopecia; Breast Neoplasms; Colonic Neoplasms; Diarrhea; Drug Eruptions; Epistaxis; Female; Floxurid | 1964 |
Is drug-induced toxicity a good predictor of response to neo-adjuvant chemotherapy in patients with breast cancer?--a prospective clinical study.
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-2-Associated X | 2004 |
[Taxol based chemotherapy in the treatment of advanced gastric cancer].
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administratio | 2004 |
[A case of advanced breast cancer markedly responding to chemo-endocrine therapy with only slight alopecia].
Topics: Adenocarcinoma, Scirrhous; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasm | 2005 |
[Second-line chemotherapy with bi-weekly CPT-11 and cisplatin for recurrent colorectal cancer resistant to 5-FU based chemotherapy].
Topics: Adult; Aged; Alopecia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cispl | 2005 |
[Pilot study of primary systemic chemotherapy with docetaxel (DOC), epirubicin (EPI) and capecitabine (Xeloda) in patients with advanced breast cancer].
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabin | 2006 |
[A patient with advanced recurrent breast cancer who firmly resisted hair loss and was then treated by combination therapy with high-dose toremifene and capecitabine].
Topics: Adult; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; C | 2007 |
Combination chemotherapy of metastatic breast carcinoma with cyclophosphamide, adriamycin, and peptichemio.
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bone Neoplasms; | 1984 |
Adriamycin, dibromodulcitol, and mitomycin combination chemotherapy for patients with metastatic breast carcinoma previously treated with cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, and prednisone.
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neopla | 1984 |
Combination chemotherapy for metastatic breast cancer with fluorouracil, adriamycin, cyclophosphamide, and methotrexate.
Topics: Alopecia; Antineoplastic Combined Chemotherapy Protocols; Bacterial Infections; Breast Neoplasms; Cy | 1984 |
Combination chemotherapy for advanced bladder cancer with adriamycin, cyclophosphamide, and 5-fluorouracil.
Topics: Actuarial Analysis; Adenocarcinoma; Alopecia; Anorexia; Antineoplastic Combined Chemotherapy Protoco | 1983 |
[Chemotherapy of metastasizing breast cancer. Adriamycin mono and combination therapy after LMFP pretreatment].
Topics: Alopecia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chlorambucil; Cyclophosp | 1983 |
Prolonged remissions of metastatic breast cancer achieved with a six-drug regimen of relatively low toxicity.
Topics: Adult; Aged; Alopecia; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast | 1983 |
VP-16 and adriamycin in patients with advanced breast cancer.
Topics: Adenocarcinoma; Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Breast Neopla | 1982 |
[Severe intoxication after combined chemotherapy of a sigma-adenocarcinoma with peptichemio and 5-fluorouracil (author's transl)].
Topics: Adenocarcinoma; Alopecia; Candidiasis, Oral; Diarrhea; Female; Fluorouracil; Hepatomegaly; Humans; M | 1982 |
Combination chemotherapy in advanced carcinoma of the cervix.
Topics: Alopecia; Antineoplastic Agents; Carcinoma; Cyclophosphamide; Doxorubicin; Female; Fluorouracil; Hum | 1982 |
Prednimustine in combination with methotrexate and 5-FU (PMF): a pilot study.
Topics: Aged; Alopecia; Breast Neoplasms; Chlorambucil; Drug Therapy, Combination; Female; Fluorouracil; Hum | 1982 |
Mitoxantrone, 5-FU, and leucovorin in breast cancer.
Topics: Adenocarcinoma; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Adm | 1994 |
[Alternative combination chemotherapy with mitomycin C, vincristine, methotrexate, 5-fluorouracil, cis-platinum and adriamycin for adenocarcinoma of the lung].
Topics: Adenocarcinoma; Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Do | 1993 |
[A case of advanced gastric cancer responding to an FAP (5-FU, ADM, platinum compounds) combined chemotherapy].
Topics: Adenocarcinoma; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplati | 1993 |
Neoadjuvant chemotherapy in locally advanced breast cancer.
Topics: Alopecia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breas | 1996 |
Patients' experiences of chemotherapy: side-effects associated with 5-fluorouracil + folinic acid in the treatment of colorectal cancer.
Topics: Adenocarcinoma; Aged; Alopecia; Antidotes; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Di | 1998 |
Intensified adjuvant cyclophosphamide, methotrexate and 5-fluorouracil therapy: a dose-finding study for ambulatory patients with breast cancer.
Topics: Adult; Aged; Agranulocytosis; Alopecia; Ambulatory Care; Antineoplastic Combined Chemotherapy Protoc | 1999 |
Longevity, stress response, and cancer in aging telomerase-deficient mice.
Topics: Aging; Alopecia; Animals; Body Weight; Bone Marrow Diseases; Fluorouracil; Hair Color; Longevity; Mi | 1999 |
Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer.
Topics: Alopecia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diarrh | 2001 |
[Advances in topical therapy of skin diseases (author's transl)].
Topics: Acne Vulgaris; Administration, Topical; Alopecia; Benzoyl Peroxide; Dinitrochlorobenzene; Fluocortol | 1979 |
Male pattern alopecia regrowth following topical fluorouracil therapy.
Topics: Alopecia; Alopecia Areata; Fluorouracil; Humans; Keratosis; Male; Middle Aged | 1977 |
Combination chemotherapy in the treatment of advanced breast cancer.
Topics: Adrenalectomy; Alopecia; Antineoplastic Agents; Breast Neoplasms; Cyclophosphamide; Drug Therapy, Co | 1976 |
[Chemotherapeutic combinations of mutually potentializing drugs. 1-Application to the treatment of breast cancers].
Topics: Aged; Alopecia; Antineoplastic Agents; Breast Neoplasms; Cyclophosphamide; Drug Synergism; Drug Ther | 1975 |
[Chemotherapeutic combinations of mutually potentiating drugs. 2-Application to the treatment of bronchial cancers].
Topics: Adult; Aged; Alopecia; Antineoplastic Agents; Bronchial Neoplasms; Carcinoma, Squamous Cell; Drug Sy | 1975 |
Treatment of advanced bronchogenic carcinoma with adriamycin and 5-fluorouracil.
Topics: Alopecia; Carcinoma, Bronchogenic; Doxorubicin; Drug Therapy, Combination; Female; Fluorouracil; Hum | 1975 |
[Pilot study of chemotherapy with mitoxantrone, ifosfamide, 5-fluorouracil in metastatic cancers of the breast. Preliminary study].
Topics: Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cause of Death; Fe | 1991 |
Toxicity and side-effects of combination chemohormonal therapy of advanced breast cancer.
Topics: Alopecia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therap | 1992 |
Intravenous or oral adjuvant CMF for node-positive breast cancer.
Topics: Adjuvants, Pharmaceutic; Administration, Oral; Adult; Aged; Alopecia; Antineoplastic Combined Chemot | 1992 |
MMAF for advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; | 1991 |
[Secondary effects of adjuvant therapy].
Topics: Alopecia; Amenorrhea; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophospha | 1985 |
Mitoxantrone, 5-fluorouracil and cyclophosphamide in advanced breast cancer.
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosph | 1988 |
Combined cytotoxic and endocrine treatment of postmenopausal patients with advanced breast cancer: preliminary results of a phase II study of the combination of prednimustine, novantrone, methotrexate, 5-fluorouracil, and tamoxifen.
Topics: Adult; Aged; Alopecia; Anthraquinones; Antineoplastic Combined Chemotherapy Protocols; Breast Neopla | 1986 |
Dermabrasion of the scalp as a treatment for actinic damage.
Topics: Aged; Alopecia; Dermabrasion; Fluorouracil; Humans; Keratosis; Male; Middle Aged; Scalp Dermatoses; | 1986 |
[Therapeutic effect of sequential doses of methotrexate (MTX) and 5-fluorouracil (5-FU) in advanced gastric cancer: comparison of intermediate-dose MTX with high-dose MTX].
Topics: Adult; Aged; Alopecia; Diarrhea; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusio | 1985 |
Mitoxantrone combined to vincristine, cyclophosphamide and fluorouracil in advanced breast cancer.
Topics: Adult; Aged; Alopecia; Anthraquinones; Antineoplastic Agents; Bone Marrow; Breast Neoplasms; Cycloph | 1985 |
Combination chemotherapy in gastrointestinal cancer.
Topics: Adenocarcinoma; Adult; Alopecia; Appendiceal Neoplasms; Diarrhea; Drug Eruptions; Fluorouracil; Gall | 1970 |
[Xeroderma pigmentosum, universal alopecia and associated neuro-ocular symptoms].
Topics: Administration, Topical; Alopecia; Brain Diseases; Fluorouracil; Glaucoma; Humans; Male; Middle Aged | 1973 |
Cancer chemotherapy by intra-arterial infusion with adriamycin.
Topics: Adult; Alopecia; Anemia; Doxorubicin; Electrocardiography; Female; Femoral Artery; Fluorouracil; Hea | 1973 |
A phase 2 evaluation of 1-(2-chloroethyl)-3-(4- methylcyclohexyl)-1-nitrosourea (NSC 95441) in patients with advanced breast cancer.
Topics: Alopecia; Blood Platelets; Breast Neoplasms; Castration; Cyclohexanes; Cyclophosphamide; Drug Evalua | 1974 |
Cyclical combination chemotherapy for advanced breast carcinoma.
Topics: Adrenalectomy; Adult; Alopecia; Bone Marrow; Bone Neoplasms; Breast Neoplasms; Castration; Cyclophos | 1974 |
Toxicity studies of fluorouracil used with adrenalectomy in breast cancer.
Topics: Adrenalectomy; Adult; Aged; Alopecia; Ataxia; Blood Platelet Disorders; Breast Neoplasms; Diarrhea; | 1972 |
Cyclophosphamide therapy in patients with advancing breast cancer following adrenalectomy and 5-fluorouracil.
Topics: Adrenal Insufficiency; Adrenalectomy; Adult; Aged; Alopecia; Breast Neoplasms; Cortisone; Cyclophosp | 1971 |
Oral administration of fluorouracil. A preliminary trial.
Topics: Adenocarcinoma; Adult; Aged; Alopecia; Bile Duct Neoplasms; Colonic Neoplasms; Diarrhea; Fluorouraci | 1968 |
Alopecia and cytotoxic drugs.
Topics: Alopecia; Cyclophosphamide; Fluorouracil; Humans; Vincristine | 1966 |